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1. INTRODUCTION 
Fertility is an essential component of reproductive health. Unfortunately, infer-
tility has become a global medical and social problem affecting approximately 
9% of reproductive-aged couples worldwide (Boivin et al., 2007; Mascarenhas 
et al., 2012). Population decline, together with a decrease in birth rates, is under 
special attention in all Europe, including Estonia (The ESHRE Capri Workshop 
Group, 2010). Nevertheless, due to discrepancies in infertility definitions used 
and deficient knowledge about characteristics and pathways related to impaired 
reproduction, infertility research has remained a discounted area of global 
health (The ESHRE Capri Workshop Group, 2004; Mascarenhas et al., 2012). 
Human assisted reproduction technology (ART) has become a widely used 
treatment option for infertile couples with various causes, with in vitro fertiliza-
tion (IVF) and intracytoplasmic sperm injection (ICSI) as the most successful 
procedures. Despite improvements in fertilization and pregnancy rates, the over-
all success rates for IVF and ICSI have remained low (Ferraretti et al., 2012). 
The outcome of IVF or ICSI procedure is highly dependent on the effectiveness 
of controlled ovarian stimulation (COS), wherefore multiple biomarkers and 
scoring systems have been developed to evaluate the successfulness of COS 
(Haller et al., 2008; Altmäe et al., 2011; Alviggi et al., 2012). As such, folli-
cular fluid constituents have been measured as they correspond to the local en-
vironment during oocyte maturation. It is relevant, that follicular fluid sample 
material is easily obtained during oocyte retrieval. However, the research on 
finding more effective and optimal follicular fluid biomarkers is ongoing 
(Revelli et al., 2009; Nel-Themaat and Nagy, 2011). 
Underlying mechanism for IVF failure can be immune activation, including 
autoimmunity (Gleicher, 2002). Several autoantibodies are more frequently de-
tected in patients with IVF treatment failure compared to women with suc-
cessful IVF treatment, among them autoantibodies directed to fertility-specific 
tissues (Pires, 2010; Zhang et al., 2012; Ying et al., 2012). Although the pre-
sence of corresponding antibodies has been shown to associate with IVF preg-
nancy failure, there is still a lot of inconsistency about their impact on infertility 
pathogenesis (Carp et al., 2012). 
The current study was carried out in the Department of Immunology, Insti-
tute of Biomedicine and Translational Medicine, University of Tartu, Estonia 
and took place in good collaboration with colleagues from the Nova Vita Clinic, 
Centre for Infertility Treatment and Medical Genetics, Estonia; Department of 
Obstetrics and Gynecology, University of Tartu, and Laboratoire d’Immuno-
logie, Faculté de Médicine, Université Henri Poincaré, Nancy, France. Research 
on infertility related immune impairments has been conducted in our laboratory 
since 1990’s, with emphasis on autoantibody repertoire in women with various 
causes of reproductive failure. To bring new beneficial insight into the role of 
immune system impairments in female infertility, the current thesis focused on:  
(1) assessing the prevalence of common and infertility related autoantibodies in 
the blood serum in women with reproductive failure and evaluating the 
13 
 
influence of these autoantibodies on IVF treatment results; (2) measuring cyto-
kines and other biomarkers from the follicular fluid of infertile women and 
evaluating their associations on oocyte and embryo quality as well as pregnancy 
results following IVF. 
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2. REVIEW OF LITERATURE 
2.1. Infertility 
Reproduction is a foundation for all living nature. According to World Health 
Organization’s (WHO) definition of health, a healthy person should be free to 
decide if or when to have children (Preamble to the Constitution of the World 
Health Organization, 1948). Unfortunately, approximately 9% of reproductive-
aged couples are affected by infertility worldwide. The prevalence of infertility 
has a broad range of 5–15% for more and less developed countries (Boivin et 
al., 2007). By definition, infertility is a couple’s inability to conceive in 12 
months, with regular sexual intercourse and without using any contraceptives 
(Practice Committee of American Society for Reproductive Medicine, 2008). 
Causes for infertility usually divide equally in-between men and women in the 
population, often affecting both partners at the same time. In up to 15% of the 
cases, though, no clinically detectable cause is found (Forti and Krausz, 1998). 
A great deal of personal choices in life, including the will for childlessness and 
delayed parturition contribute to reduced fertility rates in Europe. However, 
genetic factors and medical conditions affecting endocrinological, gynaecologi-
cal and immunological health reduce fecundity (The ESHRE Capri Workshop 
Group, 2010). Moreover, since diagnostic methods used today still leave many 
cases undetected, mechanisms of reproductive failure remain poorly understood 
(The ESHRE Capri Workshop Group, 2004). 
 
 
2.1.1. Female infertility 
The etiology of female infertility can be defined under multiple diseases (Table 
I) (Forti and Krausz, 1998). However, the most influential physiological compo-
nent is the age of a woman. Similarly, genetic propensity, environmental fac-
tors, including smoking the cigarettes and substance abuse, malnutrition and 
over- or underweight play also a great role (The ESHRE Capri Workshop 
Group, 2002).  
 
 
Table I. Non-genetic causes of female infertility (based on Forti and Krausz, 1998) 
Ovulatory dysfunction 
Premature ovarian failure (POF) 
Polycystic ovary syndrome (PCOS) 
Tubal obstructions 
Tubal factor infertility (TFI) 
Endometriosis 
Vaginal and cervical factors 
Uterus abnormalities 
Unexplained infertility 
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Ovulatory dysfunction 
Impairments in the endocrine system can lead to anovulatory infertility either 
with hypo-, hyper-, or normal levels of gonadotropic hormones. During hypo-
gonadotropic hypogonadism, the reduced secretion of pituitary follicle stimu-
lating hormone (FSH) and luteinizing hormone (LH) hinder ovulation. This 
condition is often seen in underweight women but also in excessively exercising 
female athletes. Elevated levels of FSH indicate ovarian failure, mainly, be-
cause of depletion of the oocytes, or, in rare cases, because of resistant ovary 
syndrome (The ESHRE Capri Workshop, 1996; The ESHRE Capri Workshop 
Group, 2002). When elevated serum FSH level is associated with amenorrhea 
and hypoestrogenism before the age of 40, the diagnosis of premature ovarian 
failure (POF) is assigned. Lately a pathophysiologically more precise term, 
primary ovarian insufficiency (POI), is preferred (Welt, 2008). The new term 
describes more accurately the state of ovarian condition, since varying degree of 
ovarian function is still preserved in some of the patients and, moreover, a small 
proportion of women with POF diagnosis may still spontaneously conceive and 
deliver (Tsigkou et al., 2008; Welt, 2008). The estimated prevalence of POF in 
women by the age 40 is approximately 1%. Two major mechanisms of POF are 
follicle dysfunction and follicle depletion. The etiology of POF, however, re-
mains mostly unknown and a variety of possible causes, including genetic, en-
vironmental and iatrogenic, have been proposed (Kokcu, 2010). Besides, an 
autoimmune basis has been detected in almost half of the POF cases as these 
patients have: (1) associated autoimmune diseases, such as Addison’s disease or 
thyroid autoimmunity; (2) autoantibodies to steroid-producing cells and/or other 
ovarian antigens and (3) lymphocytic oophoritis (Hill et al., 1990; Lebovic and 
Naz, 2004; Carp et al., 2012; Kokcu et al., 2012). 
Women with normogonadotropic anovulation reveal serum levels of FSH 
and LH within normal range. Normogonadotropic anovulation can often be cau-
sed by adrenal hyperandrogenism or polycystic ovary syndrome (PCOS) (The 
ESHRE Capri Workshop, 1996; The ESHRE Capri Workshop Group, 2002). 
Although PCOS is the leading endocrine disorder in women, with prevalence up 
to 15%, there is still a lot unknown in the etiology of this disease. The clinical 
expression of this syndrome can be variable, generally including oligo- or an-
ovulation, hyperandrogenism and polycystic ovaries. These women may suffer 
from subfertility due to the impact of obesity, hyperinsulinemia or –andro-
genism and endocrine irregularities on folliculogenesis and endometrial recep-
tivity. Furthermore, because of the factors listed, these patients are more prone 
to develop pregnancy associated complications, like gestational diabetes or 
hypertension. Insulin resistance, commonly seen in obese PCOS patients, 
increases the risk of developing type II diabetes in these women (Fauser et al., 
2012). Additionally, autoimmune thyroiditis is significantly more prevalent in 
PCOS patients than in controls without PCOS (Janssen et al., 2004). Therefore, 
an autoimmune implication has been suspected in the etiopathogenesis of PCOS 
cases that are associated with other autoimmune diseases, as these patients are 
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also positive for several autoantibodies (Luborsky, 2002; Petríková and 
Lazúrová, 2012).    
 
Tubal obstructions 
Tubal factors account for 25–35% of infertility cases. Causes for damaged fallo-
pian tubes include pelvic inflammatory disease (PID), endometriosis and pelvic 
surgery. As a result, the transport of either spermatozoids or fertilized oocyte is 
impaired or even impossible (The Practice Committee of the American Society 
for Reproductive Medicine, 2006b). PID is a widely spread significant sequelae 
of sexually transmitted diseases (STD) among non-pregnant women of repro-
ductive age. Long-term complications due to PID can be tubal factor infertility 
(TFI), ectopic pregnancy and chronic pelvic pain. Long term complications are 
mostly associated with the coinfection of Chlamydia trachomatis and Neisseria 
gonorrhoeae (Sweet, 2011). The induction of proinflammatory cytokines [tu-
mor necrosis factor (TNF)-α and interleukin (IL)-1] after chlamydia or gono-
cocci infection can damage the epithelium of the fallopian tubes causing thereby 
loss of function. In addition, hydrosalpinx fluid contains prostaglandins, leuko-
trienes and lymphocytes that can eventually have deleterious inflammatory ef-
fects also on the uterine environment, influencing thereby negatively implant-
ation of an embryo (Meyer et al., 1997; Camus et al., 1999; Maisey et al., 2003; 
Bontis and Theodoridis, 2006). Further evidence of deviations in the regulation 
of local immune response in TFI patients is provided by the significantly higher 
levels of serum autoantibodies, which may also harm the function of fallopian 
tubes and endometrium (Van Voorhis and Stovall, 1997; Stern et al., 1998; 
Choudhury and Knapp, 2001; Reimand et al., 2001).  
Endometriosis, a chronic inflammatory disease characterized by the presence 
of endometrial glands and stroma outside the uterus, affects up to 10% of repro-
ductive age women. The main manifestations are pelvic pain and infertility 
(Burney and Giudice, 2012). Diverse causes for reduced fertility have been de-
scribed in these patients, as they have disturbances in folliculogenesis, funct-
ional disorders in fallopian tubes and impaired implantation of the embryo into 
the endometrium (Halis and Arici, 2004; de Ziegler et al., 2010). Endometriosis 
is also characterized by inflammatory status of the immune system, for example 
impaired natural killer cell activity and macrophage function. Overexpression of 
proinflammatory and embryotoxic cytokines in the peritoneal fluid creates an 
inflammatory milieu not only in the peritoneum but also in the eutopic endo-
metrium (de Ziegler et al., 2010; Burney and Giudice, 2012). Besides, a high 
concordance of autoimmune diseases is observed in infertile women with endo-
metriosis, as well as significantly higher prevalence of autoantibodies against 
endometrium, ovary and phospholipids, to name a few. Therefore, endometri-
osis is sometimes considered as an autoimmune disease (Matarese et al., 2003; 
Burney and Giudice, 2012). 
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Unexplained infertility 
Unexplained infertility is a diagnosis made by exclusion, when standard investi-
gations used in everyday clinical approach (tests of ovulation, tubal patency and 
semen analysis) are normal in an infertile couple (The Practice Committee of 
the American Society for Reproductive Medicine, 2006a). The prevalence of 
unexplained infertility in infertile women varies from 21–26%, increasing with 
patients age (Maheshwari et al., 2008). The causes for unexplained infertility 
are heterogeneous. Female age is thought to be the major influencing factor 
(The ESHRE Capri Workshop, 1996; Maheshwari et al., 2008), but immune 
system impairments  (Putowski et al., 2004; De Carolis et al., 2010), genetic 
factors (Altmäe et al., 2009) and subclinical endocrinological diseases 
(Dmowski, 1995) have been suspected as much. In patients with immune sys-
tem impairments, discrepancy between the T helper lymphocyte (Th)1-Th2 res-
ponses towards the pregnancy not favoring Th1 profile has been detected. 
Consequent imbalance in cytokine profile may in one’s turn lead to changes in 
uterine natural killer cell number and activation status, which may additionally 
contribute to implantation failure in unexplained infertility patients (Perricone et 
al., 2008; De Carolis et al., 2010). 
 
 
2.1.2. Male infertility 
To diagnose male factor infertility, the male partner is studied by his medical 
history and physical examination, including semen analysis according to stan-
dards set by the WHO (Cooper et al., 2010; World Health Organization, 2010). 
The most common cause for male infertility is varicocele, affecting around 20% 
of men in general population and up to 40% of infertile men (Nagler and 
Grotas, 2009). It is a condition that involves dilatation of scrotal veins. Links 
between varicocele and testicular dysfunction have remained obscure, with ve-
nous reflux and testicular temperature elevation as one of the possible culprits 
(The Practice Committee of American Society for Reproductive Medicine, 
2008). However, increase in seminal levels of proinflammatory cytokines and 
oxidative stress as well as reduced total antioxidant capacity have been sus-
pected as much (Nallella et al., 2004; Moretti et al., 2009). Besides, in the 
pathophysiology of varicocele impaired spermatogenesis because of auto-
immunity has been proposed (Gilbert et al., 1989; Naughton et al., 2001). In-
fertility in the male due to immunological causes is mostly associated with 
antisperm antibodies (ASA), which can develop as a result of testicular damage, 
infection or inflammation. As a consequence, sperm antigens are able to pass 
through blood-testis barrier and may activate corresponding antigen-specific T- 
and B lymphocytes. ASA can affect sperm quality and fertilization capacity by 
causing sperm agglutination, inhibiting sperm mobility and impairing sperm 
capacitation and acrosome reaction. In the female, ASA can additionally disrupt 
sperm-oocyte fusion, act embryotoxic or hamper embryo implantation by 
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binding to the hatching embryo (Koide et al., 2000; Choudhury and Knapp, 
2001; Chamley and Clarke, 2007). 
Male infertility can additionally be caused by congenital genetic factors, for 
example anomalies at the chromosomal or DNA level. The first group includes 
abnormalities in the number of sex chromosomes, with XXY as the commonest, 
microdeletions of the Y chromosome and structural anomalies. Monogenic de-
fects leading to male infertility are mostly autosomal recessive, including 
congenital bilateral absence of the vas deferens and hormonal deficiencies due 
to defects in hormone synthesis or the respective receptor. Similarly, hypogona-
dism, STD and testicular cancer can lead to male infertility (The ESHRE Capri 
Workshop, 1996; The ESHRE Capri Workshop Group, 2002).  
 
 
2.2. In vitro fertilization (IVF) 
Assisted reproductive technology has become a hopeful treatment for infertile 
patients. Since the birth of the first IVF baby in 1978 over 5 million babies have 
been born worldwide using ART (Steptoe and Edwards, 1978; ESHRE, 2013). 
Introduction of ICSI in 1992 as a treatment for severe male infertility was a 
major breakthrough in the field of ART and quickly became a widely used 
procedure in many other indications for assisted reproduction (The ESHRE 
Capri Workshop Group, 2007). Approximately 947 IVF procedures per million 
inhabitants were performed in Europe in year 2008 and about 0.5–4.6% of all 
infants born were ART-babies. The ratio of ICSI to conventional IVF has re-
mained 2 to 1 (Ferraretti et al., 2012). 
The process of these two treatments can be divided into 3 stages. The first 
phase is COS. During this step, ovaries are stimulated with administrating exo-
genous FSH following either gonadotropin-releasing hormone (GnRH) antago-
nists’ or agonists’ protocol, to mature multiple oocytes (Macklon et al., 2006). 
At the second stage, cumulus-oocyte complexes are collected by ultrasound-
guided transvaginal follicle aspiration, followed by insemination or injection 
with spermatozoa either in case of conventional IVF or ICSI, respectively. The 
oocytes are routinely monitored to confirm fertilization 16–18 h later and 
assessed for embryo cleavage a day after. As the final phase, selected embryo(s) 
are transferred to the uterus 2 or 3 days after fertilization. In order to avoid the 
development of multiple pregnancy, only 1 or 2 embryos are transferred at the 
time (Salumets et al., 2003). 
The fertilization rate is quite high, reaching up to 80% depending on the 
ART method used (Rienzi et al., 2012). Still, implantation rate remains as low 
as 10–15% (Macklon et al., 2006) wherefore the mean pregnancy rate per 
embryo transfer procedure remains around 30% for both, IVF and ICSI 
(Ferraretti et al., 2012). The putative outcome of IVF or ICSI is largely depen-
dent on the success of the COS, which is why besides embryo morphology 
evaluation multiple parameters or scoring systems are used to evaluate the 
effectiveness of COS (Salumets et al., 2001; Salumets et al., 2003; Haller et al., 
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2008; Altmäe et al., 2011; Rienzi et al., 2011; Alviggi et al., 2012). Never-
theless, there are no direct diagnostic tests to measure the quality of folliculo-
genesis, not to mention the physiologic function of the fallopian tubes or 
mechanisms of embryo implantation (The ESHRE Capri Workshop Group, 
2004). Therefore, the need remains to discover more effective biomarkers along 
with more effective protocols to predict the success of IVF treatment (Macklon 
et al., 2006; Nel-Themaat and Nagy, 2011). 
As indicated above, the relatively low implantation rates in IVF and ICSI 
may additionally be contributed by immune system interference. Supraphysio-
logical concentrations of sex steroids that are achieved during COS are asso-
ciated with reduced implantation rates after IVF embryo transfer (Simon et al., 
1995; Macklon et al., 2006). According to one hypothesis, they may exert an 
immunomodulatory effect through the hypothalamic–pituitary–gonadal axis 
(Beagley and Gockel, 2003; Cutolo et al., 2004). Secondly, the enhancing role 
of estrogens on autoimmunity may lead to autoantibody formation often seen in 
IVF patients, which can be detrimental for implantation (Ansar Ahmed et al., 
1985; Birdsall et al., 1996; Geva et al., 1997; Stern et al., 1998; Beagley and 
Gockel, 2003; Cutolo et al., 2004). Further on, microtrauma during oocyte 
retrieval could induce the production of anti-ovarian autoantibodies (AOA) that 
can lead to poor IVF outcome (Geva et al., 1997; Monnier-Barbarino et al., 
2003; Forges et al., 2006; Haller et al., 2007). However, debate over immune 
system interference in IVF and ICSI is ongoing and subject to further investi-
gation. 
 
 
2.3. The anatomy and physiology of the human ovary 
Human ovary possesses two main functions: production of germ cells and bio-
synthesis of steroid hormones (Palma et al., 2012). Ovary is surrounded by a 
connective tissue capsule called tunica albuginea. The interior part of the ovary, 
called ovarian stroma, consists of two layers: ovarian cortex and medulla. Ova-
rian medulla contains blood vessels, nerves and endocrine cells. The cortex may 
contain ovarian follicles in the different developmental stages, such as resting, 
maturing and atretic follicles as well as corpus luteum and its remnants (Figure 1) 
(Fritsch, 2008). 
During fetal development primordial germ cells, that have colonized the 
gonadal tissue, undergo extensive mitotic division. By the 20th week of gesta-
tion their number reaches up to 6 million cells. From there on, the ovarian re-
serve starts to continuously decrease throughout a woman’s reproductive life 
span, first by oogonial atresia, but from puberty on, also by folliculogenesis. 
Therefore, at birth, about 1 million primordial follicles are present in the ovarian 
cortex and only 300,000–400,000 remain at puberty (Oktem and Oktay, 2008). 
Changes in the hypothalamic-pituitary axis negative feedback lead to initiation 
of folliculogenesis and onset of puberty (Messinis, 2006). Folliculogenesis 
starts with development of primordial follicles, surrounded by a single layer of 
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flat granulosa cells, into primary follicles, surrounded by a single layer of 
cuboidal granulosa cells. Granulosa cells further stratify: (1) into cumulus 
granulosa cells surrounding oocyte and forming cumulus-oocyte complex, and 
(2) into mural granulosa cells, which form the inner lining of the follicular basal 
lamina. Thus a secondary follicle is formed. Also, the thecal layer, which con-
tains androgen-producing cells, starts to form around the granulosa. Mature 
Graafian follicle is distinguished from secondary follicle by the antrum filled 
with fluid. During ovulation, the cumulus-oocyte complex is released and fol-
licle starts to develop into corpus luteum. Progesterone, synthesized by corpus 
luteum, is essential for maintaining the menstrual cyclicity and early pregnancy 
(Fritsch, 2008; Matsuda et al., 2012). 
Cortex
Medulla
Primordial follicles
Developing follicles
Mature Graafian follicle
OvulationGranulosa cells
Oocyte
Antrum filled with 
follicular fluid
Polar body
Secondary oocyte
Corpus luteum
Corpus albicans
Figure 1. Ovarian structure and follicular development. 
 
 
2.3.1. Regulation of the follicular cycle  
with emphasis on granulosa cells 
Follicular development is regulated by various endocrine, paracrine and auto-
crine factors (Figure 2). The survival of preovulatory follicles is mediated 
through gonadotropins, estrogens, growth factors and cytokines, to name a few. 
Whereas the apoptosis stimulating fragment (Fas)/Fas ligand, TNF-α and B cell 
leukemia (Bcl)-2 family proteins stimulate follicular apoptosis (Revelli et al., 
2009; Matsuda et al., 2012).  
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Hormones 
Two critical hormones of the female reproductive cycle are pituitary gonado-
tropins FSH and LH. Their secretion is stimulated by GnRH from the hypo-
thalamus. In women, FSH is responsible for antral stage follicular growth and 
selection of the dominant follicle. FSH also promotes estradiol synthesis by 
granulosa cells. LH is responsible for stimulating androgen production by theca 
cells and ovulation of the dominant follicle (Gougeon, 2010; Baerwald et al., 
2012). Gonadotropins act synergistically with estradiol, which is produced by 
granulosa cells. Estradiol influences ovarian folliculogenesis through the nega-
tive feedback mechanism of the hypothalamic–pituitary system, where estradiol 
decreases FSH release. Additionally, estradiol is important in the positive feed-
back mechanism, where it sensitizes pituitary to GnRH (Messinis, 2006). All in 
all, estradiol promotes folliculogenesis, increases the expression of gonado-
tropin receptors and inhibits granulosa cell apoptosis and subsequent follicular 
atresia (Matsuda et al., 2012). 
 
 
 
Figure 2. Regulators of the ovarian cycle in follicular fluid. 
 
 
Growth factors 
The follicular fluid contains multiple growth factors secreted from the granulosa 
cells with insulin-like growth factor (IGF)-I as the most essential and well de-
scribed. IGF-I supports granulosa cell proliferation and inhibits apoptosis. It 
also takes part of dominant follicle selection by increasing the responsiveness to 
gonadotropins of the more developed follicle (Revelli et al., 2009; Matsuda et 
al., 2012). The mammalian transforming growth factor (TGF)-β superfamily 
has over 40 proteins, including activins, inhibins, bone morphogenetic proteins 
and growth differentiation factors, that are involved in cell proliferation, growth 
and differentiation (Knight and Glister, 2006; Trombly et al., 2009). TGF-β 
additionally influences cell migration and production of other growth factors. 
Follicular fluid TGF-β is important in follicular growth, meet oocyte quality and 
embryo implantation, since higher levels of TGF-β in the follicular fluid of IVF 
patients show positive associations with the number of fertilized oocytes and 
pregnancy achievement (Fried and Wramsby, 1998). Another growth factor 
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produced by granulosa cells is granulocyte-colony stimulating factor (G-CSF), 
which plays important roles in proliferation and terminal differentiation of 
neutrophils, reduction of the production of proinflammatory cytokines in acti-
vated macrophages, and endothelial cell proliferation and migration (Barreda et 
al., 2004). In follicular fluid, a role for G-CSF in the oocyte maturation has 
been proposed by several studies (Salmassi et al., 2004; Ostanin et al., 2007). 
Moreover, Ledee and colleagues suggested the level of follicular fluid G-CSF to 
be used as a biomarker for oocyte selection for ART (Lédée et al., 2011). 
 
Interleukins 
Cytokines as the modulators of the immune system, also participate in the regu-
lation of the ovarian cycle by supporting follicular growth as well as guiding the 
infiltration and activation of leucocytes necessary for ovulation and tissue 
remodeling during follicular rupture, luteinization and luteolysis (Büscher et al., 
1999; Revelli et al., 2009). For example IL-6 may contribute to oocyte matur-
ation, since lower levels of IL-6 in the preovulatory follicular fluid were 
associated with IVF pregnancy failure (Kawasaki et al., 2003; Bedaiwy et al., 
2007). On the other hand, higher levels of IL-6 have been detected in women 
with ovarian hyperstimulation syndrome and endometriosis (Rizk et al., 1997; 
Garrido et al., 2000). Therefore, the exact physiological role of IL-6 in ovarian 
physiology is worth to investigate (Kawasaki et al., 2003). IL-1β, another pro-
survival factor that rescues granulosa cells from apoptosis, is also one of the 
main cytokine mediators in follicular rupture (Kaipia and Hsueh, 1997; 
Vassiliadis et al., 2005; Matsuda et al., 2012). Besides, IL-1β is a potent regu-
lator of local inflammation and is involved in the activation and migration of 
lymphocytes and endothelial cells (Terranova and Rice, 1997; Gérard et al., 
2004; Kanaji et al., 2011).  
Several other cytokines have been measured in follicular fluid, but their role 
in the follicular cycle still remains controversial. IL-18, formerly known as 
interferon (IFN)-γ inducing factor, is a potent mediator of innate and adaptive 
immune responses (Nakanishi et al., 2001; Vujisic et al., 2006). In the mouse 
ovary, IL-18 and its receptor are involved in maturation of the cumulus-oocyte 
complex and ovulation (Tsuji et al., 2001). In humans, preovulatory follicular 
fluid levels of IL-18 correlate with the number of retrieved oocytes (Gutman et 
al., 2004). However, the function of IL-18 in human ovarian physiology has re-
mained greatly understudied. IL-18 shares a synergistic action with IL-12, a 
powerful regulator of cell-mediated immune responses (Langrish et al., 2004). 
IL-12 has been thought of as a Th1 cytokine, with the ability to down-regulate 
important processes for a successful pregnancy, such as Th2 responses and 
angiogenesis (Gazvani et al., 2000). Therefore, a negative influence of IL-12 on 
reproductive physiology has been suggested by some investigators  (Gazvani et 
al., 2000; Bedaiwy et al., 2007; Lédée et al., 2008), while others argue against it 
(Gallinelli et al., 2003). Together with IL-12, IL-23 represents the bridge be-
tween innate and adaptive immune responses. These two cytokines share many 
similarities in structure and source of production because of the p40 common 
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subunit. IL-23 is a key player in controlling acute infections, chronic inflam-
matory autoimmune diseases and holds a substantial role in memory responses 
of T-cells (Langrish et al., 2004). To date, there are only few studies that have 
detected IL-23 or IL-12/IL-23 common subunit p40 from follicular fluid 
(Vujisic et al., 2006). However, studies in mice suggest a connection between 
IL-23 and the length of estrous cycle (Enright et al., 2011).  
 
Interferons 
The importance of IFNs secreted into the follicular fluid in ovarian function has 
remained unknown. The type I interferon, IFN-α is mostly known for its anti-
viral activity. It can also exert the induction of apoptosis and suppression of cel-
lular growth (Rizza et al., 2010). Also, IFN-α is suggested to favor folliculo-
genesis (Zidovec Lepej et al., 2003; Lee et al., 2009). The type II interferon, 
IFN-γ is a proinflammatory cytokine related to inflammatory processes in auto-
immune diseases (Damsker et al., 2010). In follicular fluid, levels of IFN-γ 
show contradictory associations. Higher follicular IFN-γ levels have been asso-
ciated with increased oocyte quality, successful IVF cycles as well as early clea-
ved embryos (Ostanin et al., 2007; Lédée et al., 2008). There are also studies, 
where no associations between follicular IFN-γ and embryo or IVF parameters 
were detected (Cerkiene et al., 2008). 
 
Apoptosis-inducing factors 
Follicular atresia is a degenerative process which occurs through an apoptotic 
mechanism. It can take place at any maturation time point of folliculogenesis, 
however, majority of the follicles undergo apoptosis during the antral stage 
(Matsuda et al., 2012). Apoptotic factors are important in maintaining tissue 
homeostasis and remodeling in the cycling ovary. Follicular atresia is initiated 
within mural granulosa cells by Fas/Fas ligand system. Interestingly, the Fas 
system also plays a part in oocyte maturation (Sarandakou et al., 2003; Matsuda 
et al., 2012). Both Fas and Fas ligand are expressed in granulosa cells of pre-
antral and antral follicles with an increasing level along the follicular maturation 
(Matsuda et al., 2012). Human apoptosis antigen (APO)-1 is a transmembrane 
receptor but exists also in a soluble form (sAPO-1). Interestingly, when binding 
with Fas ligand the transmembrane receptor induces apoptosis, whereas the 
soluble form inhibits it by preventing death signal transduction (Sarandakou et 
al., 2003). Similarly, TNF-α can induce apoptosis in follicular granulosa cells or 
stimulate cell proliferation instead, by binding either to TNF receptor 1 or 2, 
respectively (Matsuda et al., 2012). One of the pathways for death ligand/death 
receptor signaling is the mitochondria-mediated apoptosis by Bcl-2 family 
members. These proteins regulate germ cell as well as somatic cell apoptosis in 
the follicles (Sasson et al., 2002; Matsuda et al., 2012). 
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Chemokines 
Ovulation is considered as an inflammation-like process in a sense that it in-
volves increased vascular permeability, immune cell infiltration, expression of 
proinflammatory cytokines and swelling of the follicular tissue (Machelon et 
al., 2000). Before ovulation, infiltration of granulocytes, monocytes and T lym-
phocytes into the area surrounding the preovulatory follicle is needed for sub-
sequent luteinization and luteolysis. For this, multiple chemokines are secreted 
into the follicular fluid by granulosa cells (García-Velasco and Arici, 1999; 
Machelon et al., 2000). A potent chemotactic cytokine, IL-8, that activates 
neutrophilic granulocytes, is additionally involved in promoting cell prolifera-
tion and angiogenesis, both of which are prerequisites for normal ovarian func-
tion (Runesson et al., 1996; Połeć et al., 2011). Proinflammatory cytokines IL-
1β and TNF-α both induce the production and secretion of IL-8 (Runesson et 
al., 1996). High intrafollicular levels of IL-8, detected in women undergoing 
IVF, imply to an inflammatory reaction in progress (Runesson et al., 1996; 
Büscher et al., 1999). Chemokines of the α-chemokine family: the two macro-
phage inflammatory proteins (MIP)-1α and MIP-1β, regulated on activation, 
normal T cell expressed and secreted (RANTES) and monocyte chemotactic 
protein (MCP)-1, are all potent chemoattractants for monocytes and T lympho-
cytes (García-Velasco and Arici, 1999). Both MIP-1s are proinflammatory 
chemokines, involved in acute and chronic inflammatory host responses, im-
mune response modulation and regulation of tissue homeostasis (Maurer and 
von Stebut, 2004). Although MIP-1α is produced by ovarian theca and granu-
losa cells, the follicular fluid levels in normal folliculogenesis are low (Dahm-
Kähler et al., 2006). In contrast, lower levels of MIP-1β are indicative to poor-
quality embryos after IVF, referring to a role of this factor in oocyte maturation 
(Ostanin et al., 2007). In addition to monocytes and T lymphocytes, infiltration 
of eosinophils and mast cells is essential for ovulation and formation of the 
corpus luteum. Chemoattractant RANTES is involved in the chemotaxis or 
activation of all of these leukocytes making it the fundamental chemokine of 
ovulatory processes (Schall et al., 1990). In follicular granulosa cells, the pro-
duction of RANTES is induced by TNF-α secretion (Aust et al., 2000; 
Machelon et al., 2000). Different from RANTES, the production of MCP-1 is 
promoted by IL-1β (Dahm-Kähler et al., 2006), but also by LH and human 
chorionic gonadotropin (hCG) (Arici et al., 1997). The latter may point to the 
implication of MCP-1 in timely follicular rupture (García-Velasco and Arici, 
1999). The involvement of MCP-1 in ovulation and oocyte maturation is 
indicated by Kawano and colleagues, who found significantly higher levels of 
MCP-1 in follicles containing mature oocytes (Kawano et al., 2001). 
 
Other factors 
Novel follicular fluid markers that might be related to follicular development 
are cluster of differentiation (CD)44 variant (v)6 and triggering receptor expres-
sed on myeloid cells (TREM)-1. CD44, a transmembrane receptor shed into the 
follicular fluid, is expressed on cumulus granulosa cells at the time of ovulation 
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(Ohta et al., 1999; Ohta et al., 2001). Different forms of CD44 are involved in 
cell adhesion, migration, infiltration, proliferation and cytokine signaling (Ponta 
et al., 2003). The isoform CD44v6 has been linked with cell motility and 
apoptosis resistance in cancer, but to our knowledge CD44v6 has not been 
studied in the follicular fluid before (Yu et al., 2010; Jung et al., 2011). TREM-
1 has mostly been studied as a marker for active and chronic inflammation in 
bacterial infections. It is a transmembrane glycoprotein that belongs to the im-
munoglobulin (Ig) superfamily. As a result of TREM-1 activation, various 
proinflammatory cytokines and chemokines are produced, TNF-α, IL-1β, IL-6 
and IL-8 among them (Bouchon et al., 2000). In a previous study we discovered 
TREM-1 expression in follicular granulosa cells (Kõks et al., 2010). Additio-
nally, TREM-1 levels have been detected in the myometrium, umbilical cord 
blood and amniotic fluid (Matoba et al., 2009; Youssef et al., 2009; Kusanovic 
et al., 2010), but to our knowledge TREM-1 has never been studied in follicular 
fluid. Interestingly, levels of TREM-1 from the bronchoalveolar lavage are in 
correlation with the severity of non-infectious tissue damage (Bingold et al., 
2011). Since follicular rupture is also a non-infectious process that involves 
tissue damage, a role for TREM-1 in ovulation facilitation might be expected. 
Taken together, ovarian folliculogenesis is a long and complex process in 
which both endocrinological and immunological factors play significant roles. 
Ovulation induction in ART can lead to follicular asynchrony, which is one of 
the reasons why more precise markers for assessing follicular maturity are nee-
ded (Pellicer et al., 1987). Besides, strict IVF legislatives in some countries 
increase the pressure to reduce overexpression of embryos (Soini et al., 2006). 
Since follicular fluid can easily be obtained during oocyte aspiration, several 
cytokines, growth factors and related proteins in the follicular fluid and in the 
ovary have been studied to use them as markers for oocyte selection and 
predicting IVF success rate (Revelli et al., 2009). However, it has become clear 
that commitment to one specific marker can lead to a dead end situation, 
wherefore the holistic approach of systems biology seems more appealing. With 
the development of new high-throughput methods, that allow simultaneous 
measuring of many analytes at once from little sample volume, the identifi-
cation of whole metabolomes or immunomes has never been easier (Revelli et 
al., 2009; Wallace et al., 2012).  
 
 
2.4. Function and structure of the human endometrium 
Endometrium is the inner mucosal membrane of the uterus with the main func-
tion to provide an optimal environment for embryo implantation. It is also im-
portant in tissue clearance and regeneration during menstruation and provides a 
first line of defense against invading pathogens. On the other hand, endo-
metrium must preserve tolerance against allogeneic sperm and the semi-allo-
geneic fetus. Therefore, a delicate balance between initiating immune response 
and tolerance must be maintained in the endometrium (Young and Loy, 2005). 
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Based on their involvement in the menstrual cycle two layers can be dis-
tinguished in the endometrium: the functionalis and the basalis (Figure 3). The 
functional layer undergoes cyclical changes and is shed if no embryo implan-
tation occurred. It is composed of a single-layered epithelium that contains cili-
ated and secretory cells, and stroma, which is a specialized connective tissue 
that has the capability to decidualize. The basal layer is not shed during mens-
truation and is therefore the source of cyclical regeneration of the functionalis. 
An average menstrual cycle takes around 28 days and can be divided into 3 
stages. It begins with the menstrual phase, during what the functional layer is 
sloughed off. The following proliferative stage marks the restoration of the 
functionalis under the influence of estrogen. The levels of estrogen peak at day 
14, on the same day when ovulation should occur in a 28 day cycle. After ovu-
lation the newly formed corpus luteum starts to produce progesterone which 
transforms the endometrium to its third stage, the secretory phase, and prepares 
it for embryo implantation. The short period on days 20–24 of the cycle, when 
the uterus is receptive for implantation, is called „the implantation window“. If 
embryo implantation does not occur, levels of estrogen and progesterone start to 
decrease and the functional layer starts to degenerate, followed by menses 
(Young and Loy, 2005; Fritsch, 2008). 
 
 
 
Figure 3. Structure of the human endometrium and phases of the menstrual cycle.  
 
 
2.5. Reproductive immune failure syndrome 
The significantly increased prevalence of autoimmune abnormalities seen in 
infertile women compared to fertile controls led Gleicher and el-Roeiy in year 
1988 to propose the definition of reproductive autoimmune failure syndrome 
(RAFS) to describe polyclonal autoimmune activation in women suffering from 
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infertility, recurrent pregnancy loss and pregnancy complications (Gleicher and 
el-Roeiy, 1988). Recently Gleicher updated the acronym to RIFS (reproductive 
immune failure syndrome) indicating a general immune activation in these wo-
men, that includes alterations in the lymphocyte population and cytokine levels 
as well as autoimmune reactions (Gleicher, 2002).  
Polyclonal B-cell activation in infertile women is reflective of a broad-based 
autoimmune activation, which generally leads to the presence of several com-
mon autoantibodies that are routinely used in diagnosis of different systemic 
autoimmune diseases, such as antiphospholipid syndrome and systemic lupus 
erythematosus (Geva et al., 1997; Gleicher, 2002; Gleicher et al., 2002; Carp et 
al., 2012). The prevalence of organ-non-specific antibodies, especially anti-
phospholipid antibodies (APA), is one of the most studied immunological risk 
factor for recurrent implantation failure in IVF treatment (Coulam and Acacio, 
2012). Targets of APA are negatively charged phospholipids and their cofac-
tors. They include antibodies against cardiolipin (ACA) and its cofactor β2-
glycoprotein I (β2-GPI), which are used for diagnosing antiphospholipid syn-
drome. Although the prevalence of APA is increased in women with recurrent 
reproductive failure compared to control population, the importance of APA in 
infertility remains controversial (Hammadeh et al., 2002; Buckingham and 
Chamley, 2009). Furthermore, other common organ-non-specific autoanti-
bodies, like anti-nuclear (ANA) and smooth muscle autoantibodies (SMA), 
have been detected in women with various causes of infertility, such as PCOS, 
TFI, endometriosis and unexplained infertility (Geva et al., 1997; Van Voorhis 
and Stovall, 1997; Reimand et al., 2001). Although some studies have shown 
associations between the presence of ANA and subsequent IVF treatment 
failure (Stern et al., 1998; Ying et al., 2012), the presence of these antibodies 
rather reflects a more general immunological activation (Geva et al., 1997; 
Gleicher, 2002). Thyroid autoimmunity has been linked with increased abortion 
and IVF failure (Bussen et al., 2000; Poppe et al., 2008; Zhong et al., 2012). 
Cross-reactivity of anti-thyroid antibodies (ATA) with zona pellucida and 
placental antigens may hamper fertilization and embryo implantation processes 
(Twig et al., 2012). Moreover, ATA have been detected in the follicular fluid, 
where they might reduce oocyte quality by antibody mediated cytotoxicity 
(Monteleone et al., 2011). Also, ATA may serve as markers for an immuno-
logic defect at the T lymphocyte level which can contribute to reduced fecun-
dity (Geva et al., 1997; Poppe et al., 2008). 
The presence of organ-specific autoantibodies peculiar for infertility or to a 
gynecological disease leading to infertility may, however, directly contribute to 
reduced fecundity in these patients (Gobert et al., 1992; Pires, 2010; Kokcu et 
al., 2012). Autoimmune attack on the ovaries through AOA can lead to ovarian 
dysfunction in patients with POF, PCOS, endometriosis and unexplained inferti-
lity (Luborsky, 2002; Forges et al., 2004; Petrikova and Lazurova, 2012). AOA 
are a heterogeneous group of antibodies that recognize several antigenic targets 
in the ovary, such as granulosa and theca cells, zona pellucida, oocyte cyto-
plasm, corpus luteum, but also gonadotropins and their receptors (Haller et al., 
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2005; Monnier-Barbarino et al., 2005; Haller et al., 2007; Pires, 2010). Endo-
metrial autoimmunity with the presence of anti-endometrial antibodies (AEA) is 
characteristic to most patients of endometriosis (Mathur et al., 1982; Fernández-
Shaw et al., 1993). These autoantibodies have also been found in women suffer-
ing from TFI, unexplained infertility and PCOS (Palacio et al., 1997; Palacio et 
al., 2006). Although the prevalence of AEA does not correlate with the severity 
of endometriosis, it related to infertility in these patients (Fernández-Shaw et 
al., 1993). The possible detrimental contribution of AEA to female reproduction 
might lay in interference with embryo implantation processes (Fernández-Shaw 
et al., 1993; Gajbhiye et al., 2008). To date, the nature of majority of AEA 
antibodies is still mostly unknown, since only a few AEA epitopes have been 
identified so far: α-enolase, transferrin and fetuin-A (Walter et al., 1995; Pillai 
et al., 1996; Lang and Yeaman, 2001). 
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3. AIMS OF THE STUDY 
The general objective of this study was to assess the presence and significance 
of humoral immune system activation in serum and follicular fluid of IVF 
patients.  
 
Accordingly, the specific aims were as follows: 
 
1. To detect and compare the presence of common autoantibodies in the blood 
serum of infertile women of different etiologies.  
2. To assess the anti-endometrial autoreactivity in sera of patients with TFI and 
endometriosis. To evaluate the association of detected autoantibodies with 
IVF treatment outcome. To identify endometrial antigen(s) related to the 
cause of infertility and IVF treatment outcome. 
3. To examine the ovarian follicular content of infertile women by measuring 
proinflammatory cytokines and other related factors in the follicular fluid. 
To interpret these findings according to the cause of infertility and infertility 
treatment outcome.    
4. To measure the level of follicular fluid and serum soluble (s)TREM-1 in in-
fertile patients with different causes. To assess associations between the 
level of sTREM-1 and infertility etiology as well as IVF treatment para-
meters.  
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4. MATERIALS AND METHODS 
4.1. Subjects and IVF 
The studies recruited women from the Nova Vita Clinic, Estonia, who under-
went IVF treatment during the time period from 2004 to 2010. All patients had 
been infertile for at least a year before entering the study. Clinical investigations 
as well as diagnoses of infertility were performed by physicians of the Nova 
Vita Clinic. The four study groups consisted of women with diverse causes for 
reproductive failure. In cases where the woman lacked known reasons for in-
fertility while in her partner decreased semen quality was detected (World 
Health Organization, 1999) the diagnosis of male factor infertility was assigned. 
TFI due to occluded fallopian tubes was diagnosed either by hysterosalpingo-
graphy or by diagnostic laparoscopy (Forti and Krausz, 1998). The main cause 
for tubal occlusion was an episode of infection (PID). Endometriosis was con-
firmed by diagnostic laparoscopy according to the classification of American 
Society for Reproductive Medicine (ASRM) (American Society for Repro-
ductive Medicine, 1997). The diagnosis for PCOS was determined according to 
The Rotterdam European Society for Human Reproduction & Embryology 
(ESHRE)/ASRM-sponsored PCOS consensus group diagnostic criteria (The 
Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group, 
2004). Unexplained infertility was assumed when the woman lacked any of the 
abovementioned reasons for infertility and her partner had normal semen qua-
lity, still the couple had suffered from infertility for more than a year. Study 
groups are further characterized in Table II. Supplemental clinical and IVF 
treatment parameters for study III and IV are shown in Paper III Table 2 and 
Paper IV Table I. 
For ovarian hormonal stimulation GnRH agonist (Diphereline; Ipsen Pharma. 
Biotech, Paris, France) or antagonist (Cetrotide; Merck Serono, Geneva, Switzer-
land) was administered with recombinant FSH (Gonal-F, Merck Serono or 
Puregon, Schering-Plough, Kenilworth, NJ, US). IVF or ICSI was conducted at 
4–6 h after oocyte retrieval, the resulting embryos were cultured up to 48 h. The 
indications for ICSI were either male factor infertility or previous oocyte 
fertilization failure. Good quality embryos were identified by the presence of at 
least four blastomeres and ≤20% fragmentation, the rate of good quality 
embryos was calculated as the proportion (%) of good quality embryos out of 
all fertilized oocytes. In most of the cycles, two embryos were chosen for 
embryo transfer. Clinical confirmation of intrauterine pregnancy was made 
using an ultrasound scan at the 6th or 7th week after embryo transfer.
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4.2. Methods used for autoantibody  
detection from serum samples 
4.2.1. Detection of common autoantibodies 
All autoantibody tests are clinically available in Autoimmunity laboratory, 
Hospital of Tartu University and have periodically been subjected to external 
quality assessment by UK NEQAS (Sheffield, UK). Indirect immunofluore-
scence (IIF) was used to detect the following autoantibodies: ANA-H and 
ANA-R on human HEp-2 cell line (Human Epithelial Cell Line type 2; Immuno 
Concepts®, Sacramento, CA, US) and rodent antigen, respectively, SMA, 
parietal cell (PCA), thyroid microsomal (TMA) and mitochondrial (AMA) 
(Reimand et al., 2001). As antigenic substrates 5 μm cryostat sections of rat 
liver and kidney, commercial HEp-2 cells, mouse stomach and human thyroid 
tissue were used in case of certain antibody test. Sera were diluted 1:10 and 
1:40 (ANA-H) or 1:100 (other antibodies). As a secondary antibody, a 1:40 
dilution of fluorescein isothiocyanate conjugated rabbit anti-human IgG 
(DAKO, Glostrup, Denmark) was applied. Test results were explored using a 
UV microscope (Olympus BX50F4, Tokyo, Japan) by the laboratory specialist. 
The antibody levels were expressed as negative or as positive at lower (1:10) or 
higher (1:40 for ANA-H and 1:100 for other antibodies) titers. Every test 
included known autoantibody positive and negative sera as corresponding 
controls.  
In-house enzyme-linked immunosorbent assay (ELISA) was used to detect 
antibodies against β2-GPI and ACA. Polystyrene 96 well microtiter plates 
(Nunc MaxiSorp, Roskilde, Denmark) were coated overnight at +4oC with 5 
μg/ml β2-glycoprotein I (Crystal Chem, Chicago, IL, US) solution in borate 
buffered saline (200 mM H3PO3, 75 mM NaCl, pH 8.4) or 50 μg/ml cardiolipin 
(Sigma, Glostrup, Denmark) solution in 95% ethanol, followed by washing and 
blocking of the plates with 0.5% (β2-GPI) or 10% (ACA) bovine serum albu-
min and 0.4% Tween-20 in borate buffered saline. After incubation with sera at 
1:100 (β2-GPI) or 1:50 (ACA) dilution, alkaline phosphatase-conjugated anti-
human IgG (DAKO, Glostrup, Denmark) was applied in dilution 1:1000 as a 
secondary antibody. Color was developed by adding 100 μl (β2-GPI) or 50 μl 
(ACA) substrate, p-nitrophenyl phosphate 1 g/l in 1 M diethanolamine buffer 
(pH 9.8). Absorbencies were read at 405 nm with 492 nm subtraction. Antibody 
levels were expressed in enzyme-immunological units (EIU) calculated accor-
ding to optical density (OD) values as follows: [(ODsample-ODnegative control)/ 
ODpositive control-ODnegative control)x100]. Cut-off values for positive and strongly 
positive results were 10 and 30 EIU (β2-GPI) or 30 and 60 (ACA). Every test 
included known autoantibody positive and negative sera as corresponding 
controls. 
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4.2.2. Detection of anti-endometrial antibodies (AEA) and 
identification of their targets 
A pool of human endometriotic tissue from 5 infertile patients, aged 31–35, was 
used as antigenic substrate. The histology of all biopsy specimens corresponded 
to the mid-secretory phase of the receptive endometrium. Tissue samples were 
first homogenized mechanically with Dounce homogenizer followed by soni-
cation for 4x15 s at 60 W (Bandelin Sonoplus HD 2200; Berlin, Germany). In 
1-dimensional gel electrophoresis 1-(DE) samples were solubilized in 2-amino-
2-(hydroxymethyl)propane-1,3-diol (Tris)-HCl buffer containing: 3% sodium 
dodecyl sulfate; 10% glycerol; 0.1 M 1,2-dithio-DL-threitol (DTT); 0.02% 
bromophenol blue and 6.25 mM Tris-HCl, pH 6.8. For 2-DE a different 
solubilization buffer was used [5 M urea, 2 M thiourea, 4% 3-[(3-cholamido-
propyl)dimethylammonio]-1-propanesulfonate, 100 mM DTT and 40 mM Tris-
HCl, pH 9.5]. 1-DE was performed on a 5–20% gradient gel using SE-600 
vertical electrophoresis system (Hoefer, San Francisco, CA, US) (Utt et al., 
2002), and the proteins were transferred onto a polyvinylidene difluoride 
(PVDF) membrane using a semi-dry electro-blotter (Hoefer). Membranes were 
blocked twice, first with a 0.2 M ethanolamine⁄glycine buffer containing 0.25 
mM polyvinyl-pyrrolidone and 25% methanol, and then with the same buffer 
containing 0.14% Tween 20, 25% methanol and 0.5% gelatin hydrolysate. Sera 
diluted to 1:100 were applied to membrane strips and incubated overnight at 
+4oC under constant shaking. As a secondary antibody, horseradish peroxidase 
(HRP)-conjugated, rabbit polyclonal antibodies against human IgA or IgG 
(Dako, Glostrup, Denmark) were used at a 1:500 dilution. To detect background 
antibody reactions, one strip was incubated only with secondary HRP-con-
jugated antibodies. Color was developed in a 50 mM sodium acetate buffer (pH 
5.0) containing 0.04% 3-amino-9-ethylcarbazole and 0.015% hydrogen pero-
xide. Reactions only detected by control staining with secondary HRP-conju-
gated antibodies were excluded from further analysis. 
The isoelectric focusing (IEF) was carried out to further substantiate results 
detected with 1-DE. For this, 7-cm Immobiline DryStrips (GE Healthcare, 
Piscataway, NJ, US) with a linear pH gradient of 3–10 in an IPGphor IEF sys-
tem (Amersham Pharmacia Biotech, Uppsala, Sweden) were used. After 12 h of 
rehydration, the following focusing parameters were applied: a current of 50 μA 
per strip and a voltage increase over 8 h from 100 V to 8000 V. The IEF was 
finished at total of 25–30 kVh. For the second dimension separation, the strips 
were placed on top of 10% polyacrylamide gels in a Mini-PROTEAN 3 Cell 
Vertical Electrophoresis System (Bio-Rad Laboratories, Hercules, CA, US). 
Following electrophoresis, gels were either stained with PageBlue Protein 
Staining Solution (Fermentas, Vilnius, Lithuania) or blotted onto PVDF memb-
ranes, as described above. The gels and blotted membranes were scanned with a 
GS-710 Imaging Densitometer (Bio-Rad). The 2-DE images were analyzed 
with Melanie software version 3 (Bio-Rad).  
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For antigen identification protein spots stained with PageBlue that corres-
ponded to serum antibody reactions on the two-dimensional immunoblots were 
analyzed with mass spectrometry by trypsin degradation (Wilm et al., 1996). 
Mascot 2.2.04 Unix software (Matrix Science, London, UK) was used to 
identify the obtained peptide fragmentation spectra in the IPI_human 
human_20081009 database, which considered the following modifications: car-
bamidomethylation, deamidation, N-terminal acetylation and methionine oxi-
dation. The search was carried out together with decoy search that included the 
following parameters: precursor accuracy of 5 p.p.m. and fragment accuracy of 
0.8 Da. The theoretical isoelectric point and molecular weight for each identi-
fied protein was calculated with the ExPASy Compute web tool (http:// 
www.expasy.org/tools/pi_tool.html). For anti-α-enolase antibody validation 
rabbit polyclonal antibodies (0.03 μg⁄ml) against human a-enolase isoform 
(ENO1; Abcam, Cambridge, UK) in combination with HRP-labeled goat anti-
rabbit IgG antibodies (Dako, Glostrup, Denmark) were used.  
 
 
4.3. Methods used for biomarker  
detection from follicular fluid 
4.3.1. Flow cytometry analysis for multianalyte testing 
In total, 16 biomarkers (divided into two 8-plexes) were evaluated from each 
individual follicular fluid sample with a commercially-available FlowCytomix 
Human Basic Kit Assay (Bender Medsystems, Vienna, Austria). The first 8-
plex consisted of: IL-23, sAPO-1/Fas, MIP-1β, MIP-1α, CD44(v6), IL-8, G-
CSF, and RANTES. The second 8-plex consisted of IL-12p70, IFN-γ, MCP-1, 
IL-6, IFN-α, IL-18, IL-1β, and TNF-α. Before sample processing, each folli-
cular fluid was thawed and centrifuged at 450 g for 10 min and the supernatants 
were used for analysis. Microspheres coated with biomarker specific antibodies 
were incubated together with sample material and biotin-conjugated secondary 
antibody mixture. After washing, streptavidin-phycoerythrin solution was added 
for the second incubation. Quantization measurements were performed by flow 
cytometer instrument FC 500 and accompanying CXP Software (Beckman 
Coulter, CA, US). For calculations the FlowCytomix Pro 2.3 Software was used 
(Bender Medsystems). Standard curves for each biomarker were generated with 
manufacturer-supplied references. The concentration of a biomarker was calcu-
lated as mean fluorescent intensity divided by single median standard curve and 
expressed in pg/ml. 
 
 
4.3.2. Enzyme-linked immunosorbent assay for soluble triggering 
receptor expressed on myeloid cells (sTREM-1) detection  
To evaluate the levels of sTREM-1 from serum and follicular fluid samples 
Quantikine® ELISA assays (R&D Systems, Inc., Minneapolis, MN, US) were 
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used. Microplates pre-coated with monoclonal antibody specific for sTREM-1 
were first incubated with sample fluid and secondly with sTREM-1 conjugate. 
The final incubation with Substrate Solution was stopped by adding Stop Solu-
tion (both solutions provided by manufacturer). The color reaction was measu-
red at 450 nm with correction at 540 nm. For each set of samples standard cur-
ves were generated with manufacturer-supplied references. The concentration of 
sTREM-1 was expressed in pg/ml. 
 
 
4.4. Statistical methods 
The R2.3.1 A Language and Environment software (Free Software Foundation, 
Boston, MA, US) was used for statistical analysis. Altogether in the four stu-
dies, the following statistical methods were used: differences between study 
groups were evaluated using t- and proportion test, paired t-test, Mann-Whitney 
U-test, and chi-square tests with the Yates’ correction. Correlations between the 
variables were evaluated by Pearson’s correlation test, crude and adjusted 
simple regression and logistic regression analysis. In Papers I and II women 
with TFI were used as a reference group as the cause for their infertility was 
believed to be more related to anatomical abnormalities than immune system 
impairments. Based on results from the first two studies, male factor infertility 
patients were chosen to be more suitable for a reference group in Papers III and 
IV. The selection of a specific test and adjusted parameters are further explained 
at the results. A p-value of < 0.05 was considered statistically significant.  
 
 
4.5. Ethical considerations 
The studies were approved by the Ethics Committee of Medical Research of the 
University of Tartu. All voluntary participants signed the written informed con-
sent. Personally identifying data was kept apart from data relating to sample 
material. 
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5. RESULTS 
5.1. The presence of common autoantibodies in the 
serum of infertile women before and after ovarian 
stimulation (Paper I) 
Antibodies to mitochondrial antigens were not detected in any of the patients. In 
women with endometriosis and PCOS antibody positivity was more frequent for 
at least one antibody at a lower titer (endometriosis only) and higher titer, com-
pared to TFI patients (Table III). We also analyzed associations between the 
prevalence of certain autoantibodies at spontaneous menstrual cycle and the 
cause of infertility using logistic regression analysis adjusted for age and the 
number of previous IVF procedures. We found higher prevalence of 1:10 SMA 
to be associated with male factor infertility [adjusted odds ratio (OR) = 20.45,  
p = 0.018], endometriosis (adjusted OR = 37.29, p = 0.008) and the number of 
previous IVF procedures (adjusted OR = 2.87, p = 0.013). In addition, higher 
frequency of 1:10 ANA-R was detected in unexplained infertility patients 
(adjusted OR = 8.79, p = 0.038) than in the reference group. When autoantibody 
levels were measured after COS, the levels of SMA, PCA, TMA, ACA and β2- 
GPI antibodies had remained unchanged. However, the levels of ANA-H were 
significantly decreased (proportion test between the patients with decreased and 
increased antibody levels, p < 0.05). 
 
 
Table III. Common autoantibodies in serum* of in vitro fertilization patients 
Cause of 
infertility (n) 
Antibodies at low 
titer a, 
% (n, 95% CI) 
Proportion 
test 
(p-value) 
Antibodies at 
high titer b, 
% (n, 95% CI) 
Proportion 
test 
(p-value) 
Tubal factor 
infertility (56) 30.4 (17, 19.2-44.3) Reference 10.7 (6, 4.4-22.6) Reference 
Male factor 
infertility (29) 37.9 (11, 21.3-57.6) N.S. 3.4 (1, 0.2-19.6) N.S. 
Polycystic Ovary 
Syndrome (21) 42.9 (9, 22.6-65.6) N.S. 23.8 (5, 9.11-47.5) < 0.05 
Endometriosis (12) 58.3 (7, 28.6-83.5) < 0.05 33.3 (4, 11.3-64.6) < 0.05 
Unexplained 
infertility (11) 36.4 (4, 12.4-68.4) N.S. 18.2 (2, 3.2-52.2) N.S. 
* Serum was obtained on the 3.–5. day of the patients’ spontaneous menstrual cycle. a Antibody-
positivity at the low titer was assessed by counting the number of positive tests at the following 
titers: 1:10 for ANA-R, ANA-H, SMA, TMA, PCA or ACA and β2-GPI present at least at the 
weak positive value. b Antibody-positivity at the high titer was assessed by counting the number 
of positive tests at the following titers: 1:100 for ANA-R, SMA, TMA; 1:10 for PCA; 1:40 for 
ANA-H or highly positive results for ACA and β2-GPI. CI – confidence interval; N.S. – 
statistically not significant (p > 0.05) 
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5.2. The prevalence and implication of  
serum AEA in patients with tubal factor infertility  
and endometriosis (Paper II) 
We identified AEA reactivity on the endometrial homogenate in the molecular 
weight range of 10–100 kDa. To compare patient’s personal antibody reactivity, 
individual AEA reactions were counted and combined into a total reaction 
number for each patient. An average ± SD of 13.7 ± 4.5 and 10.3 ± 3.5 IgA 
AEA reactions were detected in patients with TFI and endometriosis, respect-
ively. According to adjusted logistic regression model, patients with TFI sho-
wed significantly more IgA AEA reactions compared to endometriosis patients 
(age and total number of IgG AEA adjusted OR = 1.2, p < 0.001). In com-
parison, the total reaction numbers of IgG AEA did not differ between the study 
groups (adjusted OR = 1.00, p = 0.100). An average of 20.8 ± 6.3 and 18.5 ± 4.8 
IgG AEA was detected in TFI and endometriosis patients, respectively. How-
ever, certain individual IgA and IgG antibody reactions showed risk associa-
tions with the cause of infertility (Table IV).  
Since no differences were detected between clinical pregnancy rates in 
women with TFI (38.7%) and endometriosis (33.3%) (age-adjusted OR = 1.66, 
p = 0.297), further analysis was conducted on the entire study group. The total 
reaction number for IgA AEA in pregnant and non-pregnant IVF patients was 
13.2 ± 4.3 and 12.1 ± 4.7 reactions, respectively. The according numbers for 
IgG AEA were 20.4 ± 6.1 and 20.3 ± 6.5 reactions, respectively. Age-adjusted 
logistic regression model showed no correlation between IVF pregnancy out-
come and the total number of IgA (adjusted OR = 0.95, p = 0.257) or IgG 
(adjusted OR = 1.0, p = 0.921) type AEA reactions. However, certain individual 
AEA reactions showed significant associations with IVF pregnancy failure 
(Table V). 
According to data found in the literature, α-enolase (47 kDa) has previously 
been suggested as an antigenic target in endometriosis (Walter et al., 1995). In 
our study, the AEA reactions against the 47-kDa endometrial antigen were pre-
ponderant in TFI patients (Table IV). Additionally, there was a difference be-
tween clinical pregnancy rates in patients with or without the 47-kDa IgA AEA 
reaction (Table V). Therefore, we aimed to validate α-enolase as an antigen for 
AEA reactions in infertile women in our study. For this, 1-DE and subsequent 
immunoblots with patients’ sera and polyclonal α-enolase antibodies were com-
pared. After finding an identical reaction in the 47-kDa region, endometrial 
antigens were separated using 2-DE (Figure 4a). The comparison of following 
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Table IV. Serum anti-endometrial antibodies that were associated with endometriosis 
and tubal factor infertility 
Antigen 
MW 
kDa 
Endometriosis  
(n = 31) 
% (n, 95% CI) 
Tubal factor infertility  
(n = 159) 
% (n, 95% CI) 
Association with 
disease: OR, p* 
IgA AEA 
95 38.7 (12, 22.4–57.7) 11.3 (18, 7.0–17.5) 5.21, < 0.001a 
73 48.4 (15, 30.6–66.6) 17.6 (28, 12.2–24.6) 4.59, 0.001a 
70 16.1 (5, 6.1–34.5) 4.4 (7, 1.9–9.2) 4.84, 0.015a 
55 3.2 (1, 0.2–18.5) 37.3 (60, 30.3–45.8) 1.06, 0.007b 
52 48.4 (15, 30.6–66.6) 86.2 (137, 79.6–90.9) 1.15, < 0.001b 
47 67.7 (21, 48.5–82.7) 84.9 (135, 78.2–89.9) 1.45, 0.015b 
45 9.7 (3, 2.5–26.9) 35.8 (57, 28.5–43.9) 1.25, 0.012b 
37 25.8 (8, 12.5–44.9) 50.9 (81, 42.9–58.9) 1.56, 0.023b 
34 6.5 (2, 1.1–22.8) 43.4 (69, 35.6–51.5) 1.10, 0.002b 
22 12.9 ( 4, 4.2–30.8) 35.8 (57, 28.5–43.9) 1.33, 0.015b 
16 19.4 (6, 8.1–38.1) 70.4 (112, 62.6–77.3) 1.11, < 0.001b 
14 6.5 (2, 1.1–22.8) 50.3 (80, 42.3–58.3) 1.08, < 0.001b 
IgG AEA 
200 12.9 (4, 4.2–30.8) 40.3 (64, 32.6–48.3) 1.33, 0.013b 
150 6.5 (2, 1.1–22.8) 41.5 (66, 33.8–49.6) 1.12, 0.004b 
130 48.4 (15, 30.6–66.6) 59.7 (95, 51.7–67.4) 1.12, 0.004b 
110 9.7 (3, 2.5–26.9) 59.1 (94, 51.0–66.8) 5.21, < 0.001b 
45 19.4 (6, 8.1–38.1) 61.6 (98, 53.6–69.1) 1.14, < 0.001b 
28 35.5 (11, 19.8–54.6) 86.8 (138, 80.3–91.5) 1.09, < 0.001b 
24 90.3 (28, 73.1–97.5) 68.6 (109, 60.6–75.5) 4.74, 0.015a 
20 90.3 (28, 73.1–97.5) 42.8 (68, 35.0–50.9) 13.32, < 0.001a 
 
* Age adjusted logistic regression (OR – odds ratio, CI – confidence interval). a Association with 
endometriosis. b Association with tubal factor infertility. AEA – anti-endometrial antibodies; MW 
– molecular weight 
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Table V. Serum anti-endometrial antibodies that were associated with probability for in 
vitro fertilization pregnancy 
IgA AEA  IgG AEA 
Antigen 
MW kDa 
Probability for pregnancy* Antigen 
MW kDa 
Probability for pregnancy* 
OR 95% CI p OR  95% CI p 
80 0.22 0.06–0.77 0.018 110 0.31 0.14–0.69 0.004 
47 0.37 0.15–0.90 0.029 100 0.37 0.16–0.85 0.020 
37 0.42 0.19–0.92 0.030 40 0.45 0.20–1.03 0.058 
32 0.44 0.21–0.94 0.034 29 0.49 0.23–1.04 0.065 
25 0.37 0.14–0.96 0.042 28 0.48 0.20–1.12 0.089 
16 0.39 0.18–0.84 0.017 14 0.28 0.08–1.00 0.049 
 
* Age adjusted logistic regression (OR – odds ratio, CI – confidence interval). AEA – anti-
endometrial antibodies; MW – molecular weight 
 
 
 
 
Figure 4. Endometrial homogenate resolved by isoelectric focusing in a pH range from 
3–10 (a). Boxes 1 and 2 show spots identified as ENO1 isoforms of α-enolase. Immuno-
blot comparison of the spots recognized: (b) the same region by ENO1 polyclonal 
antibodies; (c) a patient’s serum IgA; (d) a patient’s serum IgG; and (e) a patient’s 
serum unreactive towards the 47 kDa antigen. 
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immunoblots with polyclonal α-enolase antibodies and sera either with or with-
out IgA or IgG AEA reactions to the 47-kDa protein (Figure 4b–d) revealed up 
to three identical spots with different isoelectric point values (5.9–7.1). Two 
spots (Figure 4a, Boxes 1 and 2) were subjected to in-gel digestion and mass 
spectrometry analysis combined with sequence database searches with a signi-
ficance threshold of p < 0.001 and an ion score cut-off of 20. In spot 1, twelve 
peptides were matched with sequence coverage of 28%. In spot 2, eleven pep-
tides were matched with sequence coverage of 37%. In both of the spots ENO1 
(IPI ID: IPI00465248) was identified.  
 
 
5.3. Associations of follicular proinflammatory  
biomarker levels with infertility etiology and IVF 
treatment (Paper III) 
The concentrations of the biomarkers detected by flow cytometry analysis are 
shown in Table VI. The associations between follicular fluid biomarker levels 
and infertility etiology were assessed using adjusted linear regression models 
and male factor infertility patients as a reference group. According to our re-
sults, women with TFI were characterized by significantly lower concentrations 
of follicular IL-1β (adjusted r = –12.6 pg/ml, p = 0.037) and IFN-α, when the status 
of smoking was included in the model (adjusted r = –13.9 pg/ml, p = 0.046). In 
endometriosis patients, higher levels of IL-23 were measured (adjusted by folli-
cular number prior to stimulation r = 157.1 pg/ml, p = 0.025). Further, PCOS 
patients had significantly higher levels of CD44(v6) (age adjusted r = 2072.7 
pg/ml, p = 0.010) and MIP-1α (adjusted for age, cause of infertility and follicu-
lar count in prestimulatory ovary r = 3111.7 pg/ml, p = 0.007). On the other hand, 
lower levels of CD44(v6) were characteristic to unexplained infertility (age ad-
justed r = –1888.4 pg/ml, p = 0.025). Additionally, we found active smoking to 
be related to elevated concentrations of CD44(v6) (adjusted for age and cause of 
infertility r = 1227.8 pg/ml, p = 0.019 vs. never-smokers) and sAPO-1/Fas (ad-
justed r = 464.9 pg/ml, p = 0.031vs. never-smokers). Likewise, the levels of 
follicular IL-23 were higher in women who had been or were smoking at pre-
sent, when compared to never-smokers (adjusted for age and cause of infertility 
r = 107.6 pg/ml, p = 0.043). Interestingly, raised concentrations of IL-23 were also 
more characteristic to women experiencing secondary infertility rather than primary 
infertility (adjusted for the cause of infertility r = 94.6 pg/ml, p = 0.043).  
Further we analyzed associations between follicular fluid biomarker concen-
trations and IVF treatment parameters. Our results indicated a positive corre-
lation between the level of IL-12 and the following infertility treatment para-
meters: (1) the number of fertilized oocytes (adjusted r = 0.15 pg/ml per every 
additional two-pronuclear zygote, p = 0.007); (2) and the proportion of good 
quality embryos (adjusted r = 0.22 pg/ml per every additional embryo, p = 0.006), 
when the data was adjusted for age, cause of infertility and follicular size. We also 
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found higher levels of follicular MIP-1β to be more characteristic to women 
achieving intrauterine pregnancy when compared to hCG-negative patients (ad-
justed for age and cause of infertility r = 48.0 pg/ml, p = 0.047). Moreover, a 
positive association was revealed between the concentrations of follicular MIP-
1β and IFN-α with the diameter of a follicle (adjusted r = 7.8 pg/ml, p = 0.037 
and r = 2.4 pg/ml for every millimeter in diameter, p = 0.023, respectively), 
regardless of age or cause of infertility. The concentration of IL-8 in follicular 
fluid was positively associated with infertility treatment parameters, such as: (1) 
intrauterine pregnancy (adjusted for age, cause of infertility, rate of good quality 
embryos transferred and endometrial thickness r = 207.5 pg/ml, p = 0.051); (2) 
parity (adjusted for age and cause of infertility r = 150.6 pg/ml for every child 
born, p = 0.039); (3) the diameter of a follicle (adjusted for age and cause of 
infertility r = 40.2 pg/ml, for every additional millimeter in diameter p = 0.005); 
(4) but also with serum progesterone after ovarian stimulation (adjusted r = 4.7 
pg/ml, p = 0.031). Similarly, the level of follicular IL-18 was positively asso-
ciated with: (1) the number of fetuses detected by ultrasonography (adjusted for 
age, cause of infertility, number of embryos transferred, rate of good quality 
embryos among them and endometrial thickness r = 67.2 pg/ml for every addi-
tional fetus, p = 0.020); (2) increased parity (adjusted for age and cause of in-
fertility r = 60.7 pg/ml for every child born, p = 0.038); (3) and the follicular 
diameter (adjusted for age and cause of infertility r = 13.1 pg/ml for every ad-
ditional millimeter in diameter, p = 0.022).  
 
 
5.4. Level of follicular fluid and serum  
sTREM-1 in infertile women (Paper IV) 
Concentrations of sTREM-1 were measured with ELISA in the follicular fluid 
[52.4–232.5 pg/ml (mean ± SD, 140.4 ± 34.4)] and blood serum [45.7–242.5 
pg/ml (115.6 ± 35.1)]. According to Pearson’s correlation test, follicular fluid 
and serum levels of sTREM-1 were in good correlation with significantly higher 
levels in follicular fluid compared to serum (t-test = 5.24, p < 0.0001). In folli-
cular fluid the levels of sTREM-1 in different patient groups were as follows: 
150.3 ± 40.5 pg/ml in patients with male factor infertility; 139.8 ± 32.4 pg/ml in 
TFI; 124.1 ± 30.4 pg/ml in women with endometriosis; 148.0 ± 28.8 pg/ml in 
PCOS and 142.0 ± 15.2 pg/ml in unexplained infertility. When we compared 
these levels using age adjusted linear regression analysis, we found that women 
with endometriosis had significantly lower levels of follicular sTREM-1 com-
pared to patients with male factor infertility (adjusted r = –25.7 pg/ml, p = 0.018). 
We found no further associations between the other patient groups and the 
reference group or with other clinical data and IVF parameters (data not shown).  
In serum, following sTREM-1 concentrations were detected in different pa-
tient groups: 118.3 ± 39.8 pg/ml in male factor infertility patients; 120.3 ± 37.6 
pg/ml in TFI; 96.9 ± 19.2 pg/ml in endometriosis; 128.7 ± 18.9 pg/ml in PCOS 
and 112.7 ± 26.2 pg/ml in patients with unexplained infertility. As in follicular 
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fluid, endometriosis patients had significantly lower levels of sTREM-1 in se-
rum when compared to the reference group (age-adjusted regression analysis  
r = –22.1 pg/ml, p = 0.030). Additionally, adjusted simple regression analysis 
revealed an association between higher levels of serum sTREM-1 and lower 
rate of embryo quality among fertilized oocytes (adjusted for age and cause of 
infertility r = –0.3% of less good-quality embryos gained per one pg/ml increase 
of serum sTREM-1, p = 0.033). Subsequent logistic regression analysis marked 
out the cutoff value of serum sTREM-1 with specificity of 95% to be between 
111.5 and 113.3 pg/ml (OR = 0.38, p = 0.048 and OR = 0.34, p = 0.028, respec-
tively). This concentration interval distinguishes whether a patient will get less 
or more than 39% of embryos with good quality. No further significant associa-
tions were found between serum levels of sTREM-1 and other clinical data or 
IVF parameters.  
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6. DISCUSSION 
6.1. Serum organ-specific and organ-non-specific 
autoantibodies in IVF patients 
Higher incidence of autoantibodies in IVF patients compared to fertile controls 
is a common observation (Gleicher and el-Roeiy, 1988; Geva et al., 1997; Van 
Voorhis and Stovall, 1997; Mettler et al., 2004; Putowski et al., 2004). Our re-
sults added further confirmation that autoimmune mechanisms are associated 
with a deteriorated uterine milieu in infertile patients. Also, in this study we in-
dicated that the prevalence of AEA IgG and IgA is associated with IVF treat-
ment results and we suggested α-enolase to be one of the antigens for AEA. 
Some studies have shown the detrimental effect of certain autoantibodies, 
such as APA, on pre-implantation embryo, decidual or placental vascularization 
and embryo implantation (Geva et al., 1997; Di Simone et al., 2010). Similarly, 
a possible association between ANA and oocyte and embryo development as 
well as embryo implantation has been suggested, as women positive for ANA 
are more prone to implantation failure and early post-implantation loss (Geva et 
al., 1997; Taniguchi, 2005; Ying et al., 2012). Others have questioned these ef-
fects, mainly associations with embryonic development, since these autoanti-
bodies are restricted to the maternal blood and do not come into contact with 
preimplantation embryos, especially in the IVF procedure. These authors have 
suggested that autoantibodies in infertile patients are markers for a broader 
immune dysfunction with reduced fecundity as one of the symptoms (Gleicher 
et al., 2002; Dias et al., 2006; Buckingham and Chamley, 2009).  
We observed notably higher numbers of common serum autoantibodies in 
infertile patients with endometriosis and PCOS than in patients with TFI. Signi-
ficantly increased prevalence of SMA was characteristic to women with endo-
metriosis. Although SMA is primarily a marker for chronic viral infections, they 
have also been more frequently detected in women with ovulatory dysfunction, 
endometriosis, TFI and unexplained infertility (Nip et al., 1995; Geva et al., 
1997; Van Voorhis and Stovall, 1997; Reimand et al., 2001). Supposedly, SMA 
could alter the function of the fallopian tubes in these women (Taylor et al., 
1989). Higher levels of SMA additionally correlated with male factor infertility 
and the number of previous IVF procedures. These are associations not easily 
explained at first notice. However, in infertile couples where reduced fertility in 
the male has been diagnosed, undetected or subclinical infertility in the female 
cannot easily be excluded. It is therefore recommendatory that both partners 
should be investigated, since the probability for coexistence of reduced female 
fecundity is higher in these couples (The ESHRE Capri Workshop, 1996). 
Whether or not the IVF procedure itself could induce autoantibody production 
has long been debated without a clear consensus, since these antibodies could 
be part of the infertile state and cause the need for multiple IVF procedures by 
their nature (Gobert et al., 1992; Fisch et al., 1995; Geva et al., 1997; Delgado 
Alves et al., 2005).  
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Our finding that the presence of ANA was characteristic to unexplained in-
fertility is in accordance with previous studies (Taylor et al., 1989; Putowski et 
al., 2004). ANA positivity is considered to be a marker for an autoimmune 
activation as it is a common finding in patients with autoimmune diseases 
(Geva et al., 1997; Dias et al., 2006). These results along with ours, allow sug-
gesting that impairments in the immune system may be involved in the etiology 
of unexplained infertility (Gleicher, 1998; Putowski et al., 2004; De Carolis et 
al., 2010). It is also possible that these patients could be suffering from sub-
clinical endometriosis or recurrent preimplantation pregnancy loss, two condi-
tions where ANA are frequently detected (Dmowski, 1995; Geva et al., 1997; 
Van Voorhis and Stovall, 1997; Coulam and Acacio, 2012).  
Multiple researches have shown that AEA reactivity to a rather wide mole-
cular weight range of antigenic targets is relevant to endometrial autoimmunity 
in cases of endometriosis (Mathur et al., 1995; Gajbhiye et al., 2008). The ori-
gin of these antibodies is explained by antigenic activation to eutopic or ectopic 
endometrium (Fernández-Shaw et al., 1993). Also, oxidative stress can chemi-
cally modify lipids and proteins causing thereby a rise in “new epitopes” 
(Shanti et al., 1999; Palacio et al., 2006). Besides endometriosis, AEA have 
been detected in PCOS, unexplained infertility and in patients with tubal 
obstructions (Palacio et al., 1997; Palacio et al., 2006). Palacio suggested with 
his colleagues a pathogenetic involvement for AEA in TFI, but the repertoire of 
AEA in TFI has not been studied much (Palacio et al., 1997). In our study, 
patients with TFI showed significantly more IgA AEA reactions compared to 
endometriosis patients. Given that IgA is a marker for local inflammation in 
mucosal tissues, our result was rather expected. Increased oviductal IgA levels 
can be caused by local inflammation in the fallopian tubes. Salpingitis can deve-
lop due to STD, although, we were unaware of any current infections among 
our IVF patients. Still, subclinical infections or sequelae of previous STD can 
similarly cause an inflammatory milieu in the fallopian tubes (Arraztoa et al., 
2002). Oviductal inflammation can eventually lead to an inflammatory milieu in 
the uterus, thereby reducing endometrial receptivity (Meyer et al., 1997; Edi-
Osagie et al., 2004; Copperman et al., 2006). Further on, as the mucosa of the 
fallopian tubes expresses genes similar to endometrial genes, AEA tissue cross-
reactivity could be believed in TFI (Quayle et al., 1998; Djahanbakhch et al., 
1999). 
Additionally, our results provide further evidence that certain AEA reactions 
are associated with IVF pregnancy failure. The presence of AEA in endo-
metriosis patients has been linked with impaired implantation and greater risk 
for miscarriage through a hindering effect on fertilization and preimplantation 
embryogenesis (Fernández-Shaw et al., 1993; Randall et al., 2007; Gajbhiye et 
al., 2008; Randall et al., 2009). From the few AEA antigens identified, anti-
bodies to fetuin-A (formerly named α2-Hermans Schmidt glycoprotein) 64 kDa 
and transferrin 72 kDa are specific and relevant to endometrial autoimmunity 
(Mathur et al., 1995; Pillai et al., 1996; Mathur, 2000). Autoimmune reactivity 
to both of these targets may contribute to infertility in endometriosis: transferrin 
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through its role in the local regulation of ovarian function and fetuin-A through 
its importance in zona pellucida formation (Mathur, 2000). Additionally, auto-
antibodies to these antigens may inhibit sperm motility (Pillai et al., 1998; 
Mathur, 2000).  
We succeeded to identify AEA reactions against the 47-kDa endometrial 
antigen, preponderant in TFI patients, as α-enolase antibodies. Interestingly, the 
α-enolase IgA AEA were additionally associated with IVF pregnancy failure. 
Enolase is a highly conserved glycolytic enzyme, important not only in the 
glycolysis cycle, but other multiple functions in a cell, making it a ubiquitous 
enzyme (Pancholi, 2001; Kim and Dang, 2005). In vertebrates, enolase exists in 
three isotypes which can form homodimers or heterodimers: α-enolase is ex-
pressed in majority of tissues; β-enolase is muscle specific and γ-enolase can be 
found in neuronal and neuroendocrine tissues (Wegner et al., 2010). The roles 
of α-enolase depend on its localization in the cell. For example, if expressed on 
cell surface, it can participate in inflammatory cell recruitment (Wygrecka et al., 
2009). Previously, α-enolase has been proposed as an antigen for AEA in endo-
metriosis (Walter et al., 1995) and for AOA in POF and unexplained infertility, 
referring to possible defective immunoregulation in the etiology of these 
diseases (Sundblad et al., 2006; Edassery et al., 2010). However, antibodies to 
α-enolase are not a disease specific marker, since they are also common to sys-
temic autoimmune diseases as well as many inflammatory and degenerative 
diseases, such as rheumatoid arthritis, systemic lupus erythematosus and auto-
immune polyglandular syndrome type 1 (Peterson et al., 1996; Pancholi, 2001; 
Shih et al., 2010; Wegner et al., 2010). Regardless, levels of α-enolase antibo-
dies can be used as prognostic markers for disease severity and prognosis (Shih 
et al., 2010).  
Polyclonal B-cell activation along with autoantibody production is only one 
of the hallmarks for RIFS, additionally including alterations in the lymphocyte 
population and cytokine levels (Gleicher, 2002). Moreover, peripheral autoanti-
bodies may not always correspond to the local situation in the female repro-
ductive tract (Geva et al., 1997). Therefore, measuring cytokines that are pro-
duced and act locally, would give us a more relevant picture of immune system 
status in reproductive tissues at certain time points (Revelli et al., 2009).  
 
 
6.2. Proinflammatory cytokines and other immunologic 
markers in the follicular fluid of IVF patients 
Follicular fluid is a metabolically active environment and contains various hor-
monal constituents such as hormones, growth factors and cytokines but also 
granulosa cells and leukocytes that are all important in oocyte maturation, sub-
sequent fertilization and embryo development (Agarwal et al., 2003). In a pre-
vious study we showed the expression of several immune response related 
genes in granulosa cells during COS in IVF treatment (Kõks et al., 2010). In the 
current study, out of the 16 immunologic markers measured from the follicular 
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fluid, ten were associated with infertility etiology or IVF treatment outcome 
(Figure 5 and 6). A limitation of this part of our approach is that the follicular 
fluid samples were not opposed to the course of each oocyte following the ferti-
lization for statistical analysis and the following results should be considered in 
the light of this. 
We detected significantly lower concentrations of follicular IL-1β in women 
with TFI. This result was rather surprising since IL-1β is a local inflammatory 
factor upregulated in microbial infection, for instance (Maisey et al., 2003). 
Furthermore, IL-1β is one of the main cytokine mediating follicular ovulation 
(Vassiliadis et al., 2005). Our finding could therefore imply that the function of 
IL-1β in the fallopian tubes and ovaries is different and impaired folliculo-
genesis might contribute to the infertility in these patients. Malfunctional folli-
culogenesis in case of TFI is further supported by lower levels of IFN-α. The 
positive role for IFN-α in folliculogenesis has been suggested previously by 
others (Zidovec Lepej et al., 2003; Lee et al., 2009). We succeeded to confirm 
this positive function, by demonstrating the association between higher folli-
cular IFN-α levels and follicular diameter. 
Systemic inflammation is common to women with PCOS (Fauser et al., 
2012). According to this, a rise in the levels of proinflammatory mediators in 
follicular fluid can be expected. We found elevated levels of MIP-1α in folli-
cular fluid of PCOS patients, which is implicated in inflammatory host respon-
ses (Maurer and von Stebut, 2004). In addition, granulosa cells of PCOS pa-
tients contain less apoptotic effectors and more cell survival factors than granu-
losa cells of healthy women (Onalan et al., 2005; Das et al., 2008). Respec-
tive imbalance could contribute to folliculogenesis defects commonly seen in 
women with PCOS (Fauser et al., 2012). Our findings of higher concentrations 
of CD44(v6) in PCOS patients indirectly support this hypothesis, since 
CD44(v6) has been linked with apoptosis resistance (Yu et al., 2010; Jung et 
al., 2011). Correspondingly, lower levels of CD44(v6) detected in unexplained 
infertility patients could point to a higher ovarian follicular apoptosis rate in 
these women. This is in accordance with a previous report where granulosa cell 
apoptosis was significantly higher in unexplained infertility patients compared 
to TFI (İdil et al., 2004). However, since there are no previous reports on 
CD44(v6) in female reproduction, the exact role of CD44(v6) in folliculo-
genesis should be further evaluated. Interestingly, we found that the status of 
active smoking was positively associated with elevated concentrations of folli-
cular CD44(v6) as well as sAPO-1/Fas, another apoptosis inhibitor (Sarandakou 
et al., 2003). Both of these associations are rather challenging to investigate, 
since smoking has previously been associated with excessive oxidative stress 
and increased granulosa cell apoptosis (Paszkowski et al., 2002; Bordel et al., 
2006). Elevated levels of follicular CD44(v6) and sAPO-1/Fas may therefore 
reflect the human body’s effort to compensate for apoptosis induction caused by 
smoking. 
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Figure 5. Follicular fluid proinflammatory biomarker profiles of women with different 
infertility etiologies. Data is presented as the proportion of the mean level of biomarkers 
in follicular fluid of male factor infertility, used as a reference. * Biomarkers that were 
significantly decreased or increased in the follicular fluid, when compared to the 
reference group (p < 0.05). 
 
 
Higher follicular levels of IL-23 were characteristic to women with endo-
metriosis and were additionally associated with smoking and secondary infer-
tility. To date, only few studies have detected IL-23 or IL-12/IL-23 common 
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subunit p40 from the follicular fluid (Vujisic et al., 2006). However, elevated 
levels of inflammatory cytokines in the follicular fluid of endometriosis patients 
are a common finding (Pellicer et al., 1998; Carlberg et al., 2000). Perhaps the 
inflammatory compliance in case of endometriosis, as concluded herein repea-
tedly, may attribute to poor oocyte quality and subsequent IVF failure (Vujisic 
et al., 2006; Xu et al., 2006). Besides, IL-23 is an important mediator in chronic 
inflammatory autoimmune diseases, indicating also to similar pathogenesis be-
tween this and endometriosis (Burney and Giudice, 2012).  
 
 
 
 
Figure 6. Schematic illustration of studied follicular fluid proinflammatory cytokines 
and chemokines that were positively associated with folliculogenesis and pregnancy 
achievement. 
 
 
Previously, some researches demonstrated a negative association between folli-
cular IL-12 and folliculogenesis, fertilization and pregnancy outcome (Gazvani 
et al., 2000; Bedaiwy et al., 2007; Lédée et al., 2008), while others revealed no 
association at all (Gallinelli et al., 2003). On the contrary, our results suggest an 
entirely positive correlation between follicular IL-12 level and the number of 
fertilized oocytes and embryo quality. Discrepancies between the results might 
be explained by differences in medical conditions recruited under the investi-
gation or the way follicular fluid was handled, either pooled or studied separa-
tely. Also, different methods used for cytokine detection vary in their sensiti-
vities and detection ranges. In fact, the mean ± SD levels of IL-12 detected by 
us (0.4 ± 2.8 pg/ml) were much lower than the ones reported previously: 
Bedaiwy et al. (24.45 ± 20.15 pg/ml in non-pregnant cycles versus 3.38 ± 10.6 
pg/ml in pregnant cycles) and Ledee et al. (15.3 ± 6.2 pg/ml) (Bedaiwy et al., 
2007; Lédée et al., 2008). These two studies suggested a deleterious function 
for IL-12 on female reproduction. Coming from that, we propose a dose-depen-
dent role for IL-12 in folliculogenesis with a positive effect in lower concentra-
tions and an adverse effect in higher levels. However, further studies are requi-
red to clarify this course. 
Two of the chemokines analyzed, MIP-1β and IL-8, showed positive asso-
ciations with follicular growth and chance for pregnancy. The role of MIP-1β 
Follicular 
development 
Oocyte fertilization 
and embryo quality 
Chance for pregnancy 
• IFN-α  
• MIP-1β 
• IL-8 
• IL-18 
• IL-12 • MIP-1β 
• IL-8 
• IL-18 
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has not been profoundly studied in female reproduction before. Ostanin and 
colleagues detected lower MIP-1β levels in the follicular fluid of women with 
poor quality oocytes and failed IVF cycles. They therefore suggested a positive 
role for MIP-1β in folliculogenesis and pregnancy establishment (Ostanin et al., 
2007). We measured higher follicular MIP-1β levels in women who achieved 
intrauterine pregnancy and found a positive correlation with the size of the 
follicle, supporting further Ostanin’s conclusions. In correspondence with pre-
vious results (Runesson et al., 2000; Fujii et al., 2003; Yoshino et al., 2003; 
Malizia et al., 2010), levels of IL-8 were positively associated with the folli-
cular diameter. Yoshino and colleagues explained the link between the size of 
the follicle and IL-8 production by presenting a connection between the grow-
ing follicular diameter and increasing hypoxia in follicles, which in turn stimu-
lates IL-8 secretion from granulosa cells (Yoshino et al., 2003). Additionally, in 
agreement with previous studies (Büscher et al., 1999; Gazvani et al., 2000; 
Yoshino et al., 2003), IL-8 was detected in all our patients. Since IL-8 can also 
be detected in the follicular fluid of unstimulated cycles (Runesson et al., 2000), 
a role for IL-8 in normal follicular physiology has been proposed (Fujii et al., 
2003). Moreover, a potential use for follicular fluid IL-8 as an indicator of suc-
cessful folliculogenesis and oocyte maturity has been suggested (Runesson et 
al., 1996; Fujii et al., 2003; Malizia et al., 2010). However, our findings that the 
concentration of IL-8 in follicular fluid was positively associated with intrau-
terine pregnancy, parity and serum progesterone after COS, are different from 
previously published data, which have shown no correlations between these 
parameters (Runesson et al., 1996; Büscher et al., 1999; Gazvani et al., 2000; 
Yoshino et al., 2003). Similar to IL-12, the contradictory results of IL-8 in our 
study and in literature may come from different study design or higher levels of 
IL-8 operated in our study (Runesson et al., 2000; Fujii et al., 2003; Yoshino et 
al., 2003; Malizia et al., 2010) Interestingly, Morelli and colleagues found that 
lower serum levels of IL-8 were indicative of extrauterine pregnancy (Morelli et 
al., 2008). The pregnancy favoring effect in serum and follicular fluid might be 
supported by growth-promoting and angiogenic role of IL-8 (Połeć et al., 2011). 
Also, our results suggest an association between the levels of follicular IL-8 and 
serum progesterone with respect to other researchers, who demonstrated the role 
of IL-8 in formation of corpus luteum (Połeć et al., 2011) and progesterone 
synthesis in the bovine (Shimizu et al., 2012). 
Regardless of the pleiotropic nature of IL-18, only a few studies have 
analyzed IL-18 in the follicular fluid (Nakanishi et al., 2001). Based on a study 
on mice, Tsuji and colleagues noted a promoting role for IL-18 in normal 
ovarian functions, such as follicular development, ovulation and luteinization 
(Tsuji et al., 2001). This was further supported by Gutman and colleagues, who 
detected a positive correlation between follicular fluid IL-18 concentrations and 
the number of retrieved oocytes after IVF procedure. They suggested a regu-
latory role of IL-18 in folliculogenesis (Gutman et al., 2004). Our finding of a 
positive association between follicular IL-18 and the diameter of the follicle 
adds further support to this. In addition, higher levels of follicular IL-18 
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correlated positively with parity in our study. Although, Kilic and colleagues 
detected no connection between follicular levels of IL-18 and pregnancy 
establishment after IVF in women with unexplained infertility (Kilic et al., 
2009), Vujisic and colleagues suggested this association in unstimulated cycles 
(Vujisic et al., 2006). To sum it up, the impact of follicular IL-18 in predicting 
IVF treatment outcome should be further studied. 
The TREM-1 was discovered in year 2000 as a transmembrane Ig super-
family receptor expressed on neutrophils and monocytes/macrophages 
(Bouchon et al., 2000). The results of the current study showed that sTREM-1 
was detectable in all follicular fluid samples, irrespective of the cause of inferti-
lity. This finding may indicate that TREM-1 is a physiologic constituent of the 
follicular fluid. Moreover, we detected a positive correlation between follicular 
fluid and serum sTREM-1 concentrations, with significantly higher levels in 
follicular fluid compared to serum. Also, our previous work showed TREM-1 
expression in floating granulosa cells in infertile women undergoing IVF (Kõks 
et al., 2010). Together, these results refer to local production of TREM-1 in the 
follicles (Salmassi et al., 2004). Since ovulation can be regarded as an inflam-
matory process, upregulation of proinflammatory cytokines and chemokines 
might be needed for normal folliculogenesis, ovulation and luteolysis. Activa-
tion of TREM-1 via an immunoreceptor tyrosine-based activation motif (ITAM)-
containing adaptor molecule increases the production on multiple proinflam-
matory cytokines and chemokines, such as TNF-α, IL-6, IL-1β, IL-8, MCP-1 
and MIP-1α (Bouchon et al., 2000; Derive et al., 2010). The soluble form of 
TREM-1, on the other hand, is thought of as a decoy receptor capable of down-
regulating the TREM-1 pathway and thereby decreasing the proinflammatory 
effect (Gibot et al., 2004a; Sharif and Knapp, 2008). The reciprocal association 
detected in the current study between higher levels of serum sTREM-1 and 
lower rate of embryo quality among fertilized oocytes may therefore reflect the 
down-regulation of proinflammatory cytokines important in folliculogenesis.  
Although TREM-1 has been shown to be upregulated during bacterial infec-
tions and sepsis (Gibot et al., 2004a; Gibot et al., 2004b), recent data show that 
TREM-1 levels can also be upregulated during non-infectious tissue damage, 
such as acute pancreatitis, chronic inflammation in rheumatoid arthritis or trau-
matic lung contusion (Cavaillon, 2009; Ferat-Osorio et al., 2009; Kuai et al., 
2009; Murakami et al., 2009; Bingold et al., 2011). These reports indicate that 
TREM-1 activation is not only initiated by pathogen-associated molecular 
patterns and Toll-like receptor activation, but can additionally be triggered by 
damage or danger associated molecular patterns via a Toll-like receptor inde-
pendent way (Cavaillon, 2009; Bingold et al., 2011). Non-infectious chronic 
inflammation is characteristic to endometriosis (Burney and Giudice, 2012). It 
was therefore surprising that endometriosis patients showed in our study signifi-
cantly decreased sTREM-1 levels, both in follicular fluid and serum samples. 
This finding is not easily explained. However, when taken into consideration 
that the cell surface TREM-1 promotes inflammatory responses, but sTREM-1 
contrarily possesses anti-inflammatory properties, our result may again point 
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towards a tendency for inflammatory milieu in the ovaries of endometriosis 
patients (Gibot et al., 2004a). 
In conclusion, infertile women with different etiologies who were included 
in the present study presented with elevated levels of autoantibody reactivity to-
wards several organ-specific and organ-non-specific autoantigens. This adds 
further proof that impairment of the immune system is characteristic to infertile 
women undergoing IVF treatment. Although some of the antibodies detected 
were related to cause of infertility or IVF treatment outcome, their pathogenetic 
role still needs to be clarified, as only few of the related antigens have been 
identified so far. We managed to identify α-enolase as an antigen for AEA. 
However, since α-enolase antibodies are commonly found in other systemic 
autoimmune and inflammatory diseases, they more likely serve as indicators for 
a defective immunoregulation in case of infertility than markers for a specific 
disease underlying infertility. We additionally found either reduced or elevated 
levels of certain proinflammatory cytokines, chemokines and apoptosis regula-
tors in the follicular fluid of IVF patients. Imbalance in the levels of immune 
system related mediators of folliculogenesis refer to ongoing impaired inflam-
matory reactions that can negatively affect folliculogenesis and subsequent IVF 
treatment outcome in these patients. On the other hand, some of the cytokines 
correlated positively with oocyte fertilization, embryo quality and pregnancy 
outcome after IVF treatment, implying thereby to their importance in normal 
ovarian function.  
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7. CONCLUSIONS 
1. Autoimmune activation, defined by the presence of organ-specific or -non-
specific autoantibodies in serum, was characteristic for women with infertility 
of different forms, with significantly higher number of common autoantibodies 
in endometriosis and polycystic ovary syndrome (PCOS) patients.  
 
2. Anti-endometrial antibodies (AEA) were detected against a wide range of 
eutopic endometrial antigens in the sera of patients with tubal factor infertility 
(TFI) or endometriosis. The prevalence of certain IgA and IgG type AEA reac-
tions varied between the study groups and had a predictive value for in vitro 
fertilization (IVF) treatment outcome. We identified α-enolase as one of the 
target antigens for AEA. The levels of α-enolase antibodies were more pre-
valent among TFI patients and were associated with pregnancy failure after 
IVF.  
 
3. Different forms of infertility were associated with distinct intrafollicular pro-
inflammatory cytokine profiles. Follicular fluid levels of some of the cytokines 
evaluated, such as IL-12, had positive correlations with oocyte fertilization and 
embryo quality, while the levels of others, including MIP-1β, IL-8 and IL-18, 
were related to successful pregnancy following IVF treatment.   
 
4. Reportedly, this study was the first to describe soluble triggering receptor 
expressed on myeloid cells (sTREM-1) in follicular fluid. Soluble TREM-1 was 
detectable in all follicular fluid samples, irrespective of the infertility etiology. 
Endometriosis patients had significantly decreased sTREM-1 levels in their 
follicular fluid and serum samples. Additionally, serum sTREM-1 concentration 
was inversely associated with embryo quality. 
 
This study provided further evidence on impairments of the immune system in 
infertile women undergoing IVF treatment and that immune system alterations 
may be involved in the infertility pathogenesis of these patients. Associations of 
certain AEA with lower chances for pregnancy could refer to antibody contri-
bution to pregnancy failure in IVF patients. Changes in follicular fluid levels of 
main cytokines regulating folliculogenesis may imply to ongoing impaired in-
flammatory reactions that negatively affect folliculogenesis and subsequent IVF 
treatment outcome in these patients. Collectively, the knowledge about presence 
and spectra of autoantibodies and intrafollicular biomarkers in IVF patients has 
the potential for application in pre-IVF treatments to raise the chances of preg-
nancy and should be evaluated as such by future prospective studies. 
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8. FUTURE PROSPECTS 
The present thesis, showing an immune activation in infertile women under-
going IVF, gives further information about impairments in immune system 
regulation. Resulting from the present study, it would be worthy to assess auto-
antibodies, as well as cytokines, from endometrial flushing. This would give a 
more relevant overview about endometrial condition before IVF embryo trans-
fer, since autoantibody detection from serum may not always correspond to the 
local situation. It would also offer a new perspective on biomarker detection and 
non-invasive prognostic method for implantation failures. Also, our today´s 
results lead us to carry out in situ hybridization on human ovaries in the future. 
We will aim to confirm the production and secretion of cytokines measured in 
the present thesis from follicular granulosa cells. 
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SUMMARY IN ESTONIAN 
Naise viljatusega kaasnev immuunsüsteemi aktivatsioon: autoantikehade ja 
põletikuliste mediaatorite tähendus 
 
Infertiilsuse ehk viljatuse all mõistetakse olukorda, kus naisel ei ole õnnestunud 
rasestuda vähemalt 12 kuud kestnud regulaarse suguelu jooksul, rasedusest hoi-
dumata. Lastetusega puutub kokku kuni 9% reproduktiivses eas paaridest. Vil-
jatus võib olla põhjustatud nii naise- kui mehepoolsetest faktoritest, kuid ligi 
15% juhtudest jääb põhjus selgusetuks. Naisepoolset infertiilsust võivad põhjus-
tada hormonaalsetest häiretest tingitud anovulatoorsed menstruaaltsüklid, muna-
juhade ja emaka patoloogiad ning autoimmunoloogilised probleemid. Mehe-
poolne viljatus võib tuleneda hormonaalsetest või meessuguorganite arenguhäi-
retest ning autoimmunoloogilistest probleemidest, mis põhjustavad muutusi 
seemnerakkude arvus, liikuvuses ja morfoloogias. 
Lähtuvalt viljatuse põhjusest kasutatakse erinevaid ravimeetodeid. Kõige 
efektiivsemaks neist on osutunud kehavälise viljastamise protseduur (IVF). 
Protseduuri esimeses etapis manustatakse naisele mõne päeva vältel folliikuleid 
stimuleerivat hormooni (FSH), et indutseerida munasarjades polüfollikuloge-
nees, kus ühe folliikli asemel küpseb korraga enamasti 15–20 folliiklit. Küpsed 
munarakud kogutakse transvaginaalselt ja viljastatakse seemnerakkudega.  
Emakasse siiratakse 1–2 kõige kvaliteetsemat embrüot 2.–3. päeval pärast 
viljastamist. Ühe IVF ravitsükli kohta on keskmine rasestumistõenäosus 30%, 
kuigi munarakkude viljastumise protsent võib küündida 80-ni.  
IVF ravi tulemuslikkus on otseselt sõltuv follikulogeneesi stimulatsiooni 
tulemuslikkusest, mille hindamiseks kasutatakse erinevaid parameetreid ja hin-
damiskriteeriume. Üheks võimaluseks on follikulaarvedeliku koostise määrami-
ne, kuna selles sisalduvad komponendid annavad relevantse ülevaate küpsevat 
munarakku ümbritsevast mikrokeskkonnast ning seeläbi ootsüüdi kvaliteedist. 
Lisaks on follikulaarvedelik kergesti kogutav munaraku aspiratsioonil. Ehkki 
siinkohal on publitseeritud mitmeid uurimistöid, jätkuvad endiselt uuringud 
efektiivsemate ja optimaalsemate biomarkerite leidmiseks, et nende põhjal pare-
mini ennustada IVF ravi edukust. IVF ravi ebaõnnestumist on seostatud mitme-
suguste organ-spetsiifiliste või -spetsiifikata autoantikehade esinemisega vilja-
tute naiste vereseerumis. Need autoantikehad võivad mõjutada follikulogeneesi 
ja munarakkude küpsemist munasarjades, takistada viljastumist munajuhades 
või embrüo implantatsiooni emakas. Vastavate märklaudvalkude vastu suunatud 
immuunreaktsioonidest on praeguseks hetkeks kirjeldatud vaid mõned. Mitmed 
relevantsed autoantikehareaktsioonid on aga siiani täpsemalt identifitseerimata. 
 
Uurimistöö eesmärgid 
 
Käesoleva doktoritöö üldeesmärgiks oli määrata viljatute naiste vereseerumis ja 
follikulaarvedelikus humoraalse immuunsüsteemi aktivatsiooni markereid ning 
58 
 
hinnata nende tähenduslikkust viljatusravi tulemusele. Selleks seadsime järgmi-
sed alaeesmärgid:  
 
1. Määrata organ-spetsiifiliste ja -spetsiifikata autoantikehade esinemist erineva 
viljatuse põhjusega naiste vereseerumis. 
2. Määrata endometrioosi ja tubaarse viljatusega patsientide vereseerumist 
endomeetriumi vastaseid antikehi (AEA) ning hinnata nende autoantikehade 
esinemise seoseid IVF ravitulemustega. Lisaks identifitseerida olulisemad 
antigeenid. 
3. Määrata proinflammatoorseid tsütokiine ja teisi biomarkereid viljatute naiste 
follikulaarvedelikus ning analüüsida saadud tulemusi vastavalt viljatuse põh-
justele ja IVF ravitulemustele. 
4. Mõõta viljatute naispatsientide vereseerumist ja follikulaarvedelikust müe-
loidsetel rakkudel ekspresseeruva aktivatsiooniretseptori lahustunud vormi 
(sTREM)-1 taset. Hinnata leitud tasemete seost viljatuse põhjuse ja IVF 
ravitulemustega. 
 
Materjal ja meetodid 
 
Uuringu esimeses osas moodustasid uuritavate grupi 129 IVF patsienti, kellel 
oli diagnoositud mehepoolne või tubaarne infertiilsus, endometrioos, polütsüs-
tiliste ovaariumide sündroom (PCOS) või seletamatu viljatus. Patsientide vere-
seerumist määrati kaudsel immunofluorestsentsmeetodil (IIF) tuuma- (ANA), 
silelihaskoe- (SMA), parietaalrakkude- (PCA), kilpnäärme mikrosoomide- (TMA) 
ja mitokondrite (AMA) vastased autoantikehad ning ensüümikaudsel immuno-
sorptsioonmeetodil (ELISA) kardiolipiini- (ACA) ja tema kofaktori β2-glüko-
proteiin I (β2-GPI) vastased autoantikehad. 
Teises uuringuetapis olid uuritavateks 190 endometrioosi ja tubaarse infer-
tiilsusega (TFI) naist, kelle vereseerumist detekteeriti immunoblotmeetodil IgG 
ja IgA tüüpi AEA. Antigeenide täpsemaks identifitseerimiseks kasutati kahe-di-
mensionaalset immunoblotanalüüsi koos tandem mass-spektromeetriaga. 
Uuringu kolmandas osas oli uuritavaid kokku 153 IVF patsienti, kellel esines 
mehepoolne või tubaarne infertiilsus, endometrioos, PCOS, seletamatu viljatus 
või muud põhjused. Uuringumaterjaliks oli folliiklite punktsioonil saadud folli-
kulaarvedelik. Patsiendi follikulaarvedelikust määrati voolutsütomeetri abil 
multiplex meetodil 16 erinevat biomarkerit: interleukiin (IL)-23, apoptoosi anti-
geen (APO-1)/Fas, makrofaagide põletikuvalk (MIP)-1α, MIP-1β, diferent-
seerumise klaster (CD)44 isovorm 6, IL-8, granulotsüütide kolooniaid stimu-
leeriv faktor (G-CSF), RANTES (regulated on activation normal T-cell expres-
sed and secreted), IL-12 subühik 70, interferoon (IFN)-γ, monotsüütide kemo-
taktiline valk (MCP)-1, IL-6, IFN-α, IL-18, IL-1β ja tuumorinekroosifaktor 
(TNF)-α. 
Neljandas uuringuetapis olid uuritavateks 110 IVF patsienti, kellel diag-
noositi mehepoolne või tubaarne infertiilsus, endometrioos, PCOS või seleta-
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matu viljatus. Uuringumaterjaliks olid patsiendi follikulaarvedelik ja veresee-
rum, millest määrati ELISA meetodil sTREM-1 taset. 
 
Tulemused 
 
Võrreldes TFI grupiga esines endometrioosi ja PCOS patsientide seas sage-
damini vähemalt üks uuritud autoantikehadest. SMA esinemine oli iseloomulik 
endometrioosi ja mehepoolse infertiilsusega naistele ning korreleerus positiiv-
selt eelnevate IVF protseduuride arvuga. Seletamatu viljatusega patsientidele oli 
iseloomulik ANA esinemine. 
Endometrioosi ja tubaarse infertiilsusega patsientidel esines nii IgA kui IgG 
tüüpi AEA. IgA tüüpi AEA reaktsioone leiti sagedamini tubaarse viljatusega 
naiste vereseerumis ning teatud IgA ja IgG tüüpi antikeha reaktsioonide esine-
mine assotsieerus halvemate IVF ravitulemustega. Kasutades kahedimensio-
naalset immunoblotmeetodit koos mass-spektromeetriaga õnnestus identifitsee-
rida ühe olulise antigeenina α-enolaasi isovorm (ENO1) molaarmassi piirkonnas 
47 kDa. ENO1 vastaseid autoantikehi esines sagedamini tubaarse infertiilsusega 
patsientidel ja ebaõnnestunud IVF ravi korral. 
Follikulaarvedelikust detekteeritud biomarkerite profiilid erinesid patsientide 
hulgas haiguspõhiselt. Tubaarse infertiilsusega patsientidel leiti oluliselt vähem 
tsütokiine IL-1β ja IFN-α. Endometrioosihaigetel oli follikulaarvedelikus tõus-
nud IL-23, PCOS patsientidel aga CD44(v6) ja MIP-1α tasemed. Seletamatu 
viljatusega naistel leiti oluliselt vähem CD44(v6). Peale selle leiti biomarkereid, 
mille esinemine oli seotud viljatusravi erinevate parameetritega. Näiteks oli IL-12 
kontsentratsioon positiivses seoses viljastatud munarakkude arvu ja embrüo 
kvaliteediga. Folliikli diameetriga assotsieerusid IFN-α, MIP-1β, IL-8 ja IL-18 
tasemed. Samuti leiti, et kõrgem MIP-1β, IL-8 ja IL-18 kontsentratsioon oli 
korrelatsioonis viljatusravi järgsete paremate rasedustulemustega. 
Lisaks seerumile oli sTREM-1 detekteeritav follikulaarvedelikus. Seerumi ja 
follikulaarvedeliku sTREM-1 tasemed olid omavahelises positiivses korrelat-
sioonis ning võrreldes seerumiga oli follikulaarvedeliku sTREM-1 kontsentrat-
sioon oluliselt kõrgem. Endometrioosihaigetel oli võrreldes mehepoolse viljatu-
sega naistega sTREM-1 tase madalam nii follikulaarvedelikus kui seerumis. Li-
saks leidsime pöördvõrdelise seose seerumi sTREM-1 kontsentratsiooni ja emb-
rüo kvaliteedi vahel. 
 
Järeldused 
 
Käesoleva väitekirja tulemuste põhjal võib järeldada, et erineva põhjusega viljatu-
tele naistele, kes läbivad IVF protseduuri, on iseloomulik üldine immuunsüsteemi 
aktivatsioon, millele viitab nii üldiste organspetsiifikata autoantikehade kui ka 
spetsiifiliselt reproduktiivorganite vastu suunatud autoantikehade esinemine vere-
seerumis. Seosed antikehade esinemise ja IVF ravi tulemuste vahel võivad osu-
tuda tõhusateks markeriteks IVF ravi edukuse hindamisel. Follikulogeneesis osa-
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levate põletikuliste tsütokiinide kontsentratsioonide erinevused võivad viidata 
follikulogeneesi häiretele, mille aluseks võivad omakorda olla muutused immuun-
süsteemi põletikuvastastes reaktsioonides. Siinkohal uuritud follikulaarsed bio-
markerid võivad leida kasutamist prognostiliste markeritena IVF ravi edukuse 
prognoosimisel. Nii seerumi autoantikehade kui follikulaarvedeliku biomarkerite 
patogeneetiline toime tuleks aga kinnitada vastavate prospektiivsete uuringutega. 
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